{
  "entities": [
    {
      "id": 1,
      "text": "Major depressive disorder",
      "type": "medical_condition"
    },
    {
      "id": 2,
      "text": "selective serotonin reuptake inhibitors",
      "type": "medication"
    },
    {
      "id": 3,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 4,
      "text": "depression-focused psychotherapy",
      "type": "treatment_type"
    },
    {
      "id": 5,
      "text": "Electroconvulsive therapy",
      "type": "treatment_type"
    },
    {
      "id": 6,
      "text": "ECT",
      "type": "treatment_type"
    },
    {
      "id": 7,
      "text": "remission",
      "type": "outcome"
    },
    {
      "id": 8,
      "text": "side effects",
      "type": "outcome"
    },
    {
      "id": 9,
      "text": "relapses",
      "type": "outcome"
    },
    {
      "id": 10,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 11,
      "text": "Monoamine oxidase inhibitors",
      "type": "medication"
    },
    {
      "id": 12,
      "text": "MAOIs",
      "type": "medication"
    },
    {
      "id": 13,
      "text": "hepatotoxicity",
      "type": "outcome"
    },
    {
      "id": 14,
      "text": "hypertensive crises",
      "type": "outcome"
    },
    {
      "id": 15,
      "text": "lethal intracranial hemorrhages",
      "type": "outcome"
    },
    {
      "id": 16,
      "text": "tricyclic",
      "type": "medication"
    },
    {
      "id": 1,
      "text": "MAOIs",
      "type": "medication"
    },
    {
      "id": 2,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 3,
      "text": "side effects",
      "type": "outcome"
    },
    {
      "id": 4,
      "text": "patients",
      "type": "patient_group"
    },
    {
      "id": 5,
      "text": "depression with atypical features",
      "type": "medical_condition"
    },
    {
      "id": 7,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 8,
      "text": "patients",
      "type": "patient_group"
    },
    {
      "id": 9,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 10,
      "text": "serotonin-norepinephrine reuptake inhibitors (SNRIs)",
      "type": "medication"
    },
    {
      "id": 11,
      "text": "effectiveness",
      "type": "outcome"
    },
    {
      "id": 13,
      "text": "Tofranil",
      "type": "medication"
    },
    {
      "id": 14,
      "text": "major depression",
      "type": "medical_condition"
    },
    {
      "id": 15,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 17,
      "text": "MAOIs",
      "type": "medication"
    },
    {
      "id": 18,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 19,
      "text": "patients",
      "type": "patient_group"
    },
    {
      "id": 20,
      "text": "major depressive disorder (MDD)",
      "type": "medical_condition"
    },
    {
      "id": 21,
      "text": "hospitalized patients",
      "type": "patient_group"
    },
    {
      "id": 22,
      "text": "outpatients",
      "type": "patient_group"
    },
    {
      "id": 23,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 24,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 25,
      "text": "adverse effects",
      "type": "outcome"
    },
    {
      "id": 26,
      "text": "fluoxetine",
      "type": "medication"
    },
    {
      "id": 27,
      "text": "TCAs",
      "type": "medication"
    },
    {
      "id": 28,
      "text": "tolerance rates",
      "type": "outcome"
    },
    {
      "id": 29,
      "text": "side effects",
      "type": "outcome"
    },
    {
      "id": 30,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 31,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 32,
      "text": "TCAs",
      "type": "medication"
    },
    {
      "id": 33,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 34,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 35,
      "text": "major depression",
      "type": "medical_condition"
    },
    {
      "id": 36,
      "text": "SNRIs",
      "type": "medication"
    },
    {
      "id": 37,
      "text": "adverse effects",
      "type": "outcome"
    },
    {
      "id": 38,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 39,
      "text": "SNRIs",
      "type": "medication"
    },
    {
      "id": 40,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 41,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 42,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 43,
      "text": "venlafaxine",
      "type": "medication"
    },
    {
      "id": 44,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 45,
      "text": "TCAs",
      "type": "medication"
    },
    {
      "id": 46,
      "text": "reboxetine",
      "type": "medication"
    },
    {
      "id": 47,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 48,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 49,
      "text": "tolerance",
      "type": "outcome"
    },
    {
      "id": 50,
      "text": "trazodone",
      "type": "medication"
    },
    {
      "id": 51,
      "text": "antidepressant",
      "type": "medication"
    },
    {
      "id": 52,
      "text": "sedative-hypnotic",
      "type": "medication"
    },
    {
      "id": 53,
      "text": "antidepressant",
      "type": "medication"
    },
    {
      "id": 54,
      "text": "nefazodone",
      "type": "medication"
    },
    {
      "id": 55,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 56,
      "text": "tolerability",
      "type": "outcome"
    },
    {
      "id": 57,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 58,
      "text": "hepatotoxicity",
      "type": "outcome"
    },
    {
      "id": 59,
      "text": "bupropion",
      "type": "medication"
    },
    {
      "id": 60,
      "text": "MDD",
      "type": "medical_condition"
    },
    {
      "id": 61,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 62,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 63,
      "text": "MDD",
      "type": "medical_condition"
    },
    {
      "id": 64,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 65,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 66,
      "text": "tolerability",
      "type": "outcome"
    },
    {
      "id": 67,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 68,
      "text": "mirtazapine",
      "type": "medication"
    },
    {
      "id": 69,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 70,
      "text": "sexual dysfunction",
      "type": "outcome"
    },
    {
      "id": 71,
      "text": "depression-related cognitive impairment",
      "type": "medical_condition"
    },
    {
      "id": 72,
      "text": "vortioxetine",
      "type": "medication"
    },
    {
      "id": 73,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 74,
      "text": "antidepressants",
      "type": "medication"
    },
    {
      "id": 75,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 76,
      "text": "drugs",
      "type": "medication"
    },
    {
      "id": 77,
      "text": "acceptability",
      "type": "outcome"
    },
    {
      "id": 78,
      "text": "antidepressants",
      "type": "medication"
    },
    {
      "id": 79,
      "text": "dropout rates",
      "type": "outcome"
    },
    {
      "id": 80,
      "text": "side effects",
      "type": "outcome"
    },
    {
      "id": 81,
      "text": "Nausea and vomiting",
      "type": "outcome"
    },
    {
      "id": 82,
      "text": "treatment discontinuation",
      "type": "outcome"
    },
    {
      "id": 83,
      "text": "sexual dysfunction",
      "type": "outcome"
    },
    {
      "id": 84,
      "text": "sedation",
      "type": "outcome"
    },
    {
      "id": 85,
      "text": "priapism",
      "type": "outcome"
    },
    {
      "id": 86,
      "text": "cardiotoxicity",
      "type": "outcome"
    },
    {
      "id": 3,
      "text": "acute suicidal ideation",
      "type": "medical_condition"
    },
    {
      "id": 4,
      "text": "ketamine",
      "type": "medication"
    },
    {
      "id": 6,
      "text": "dizziness",
      "type": "outcome"
    },
    {
      "id": 10,
      "text": "psychosis",
      "type": "outcome"
    },
    {
      "id": 12,
      "text": "urological dysfunction",
      "type": "outcome"
    },
    {
      "id": 16,
      "text": "vomiting",
      "type": "outcome"
    },
    {
      "id": 17,
      "text": "cardiovascular symptoms",
      "type": "outcome"
    },
    {
      "id": 19,
      "text": "hydroxynorketamine",
      "type": "medication"
    },
    {
      "id": 20,
      "text": "S-ketamine",
      "type": "medication"
    },
    {
      "id": 21,
      "text": "esketamine",
      "type": "medication"
    },
    {
      "id": 22,
      "text": "memantine",
      "type": "medication"
    },
    {
      "id": 24,
      "text": "dextromethorphan/bupropion",
      "type": "medication"
    },
    {
      "id": 25,
      "text": "lanicemine",
      "type": "medication"
    },
    {
      "id": 28,
      "text": "rapastinel",
      "type": "medication"
    },
    {
      "id": 29,
      "text": "basimglurant",
      "type": "medication"
    },
    {
      "id": 31,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 32,
      "text": "psychotherapy",
      "type": "treatment_type"
    },
    {
      "id": 33,
      "text": "Major depressive disorder",
      "type": "medical_condition"
    },
    {
      "id": 35,
      "text": "Imipramine",
      "type": "medication"
    },
    {
      "id": 37,
      "text": "Nortriptyline",
      "type": "medication"
    },
    {
      "id": 41,
      "text": "Fluoxetine",
      "type": "medication"
    },
    {
      "id": 44,
      "text": "Paroxetine",
      "type": "medication"
    },
    {
      "id": 47,
      "text": "Venlafaxine",
      "type": "medication"
    },
    {
      "id": 49,
      "text": "Reboxetine",
      "type": "medication"
    },
    {
      "id": 55,
      "text": "Mirtazapine",
      "type": "medication"
    },
    {
      "id": 56,
      "text": "1958",
      "type": "quantitative_result"
    },
    {
      "id": 57,
      "text": "1959",
      "type": "quantitative_result"
    },
    {
      "id": 58,
      "text": "1992",
      "type": "quantitative_result"
    },
    {
      "id": 59,
      "text": "1961",
      "type": "quantitative_result"
    },
    {
      "id": 60,
      "text": "1987",
      "type": "quantitative_result"
    },
    {
      "id": 61,
      "text": "1998",
      "type": "quantitative_result"
    },
    {
      "id": 62,
      "text": "2007",
      "type": "quantitative_result"
    },
    {
      "id": 63,
      "text": "1992",
      "type": "quantitative_result"
    },
    {
      "id": 64,
      "text": "2002",
      "type": "quantitative_result"
    },
    {
      "id": 65,
      "text": "1999",
      "type": "quantitative_result"
    },
    {
      "id": 66,
      "text": "2008",
      "type": "quantitative_result"
    },
    {
      "id": 67,
      "text": "2004",
      "type": "quantitative_result"
    },
    {
      "id": 68,
      "text": "1981",
      "type": "quantitative_result"
    },
    {
      "id": 69,
      "text": "2003",
      "type": "quantitative_result"
    },
    {
      "id": 70,
      "text": "2003",
      "type": "quantitative_result"
    },
    {
      "id": 71,
      "text": "2013",
      "type": "quantitative_result"
    },
    {
      "id": 72,
      "text": "2011",
      "type": "quantitative_result"
    },
    {
      "id": 73,
      "text": "1997",
      "type": "quantitative_result"
    },
    {
      "id": 74,
      "text": "2019",
      "type": "quantitative_result"
    },
    {
      "id": 75,
      "text": "3 to 4 times",
      "type": "quantitative_result"
    },
    {
      "id": 3,
      "text": "Cognitive-behavioral therapy (CBT)",
      "type": "treatment_type"
    },
    {
      "id": 7,
      "text": "mindfulness-based cognitive therapy (MBCT)",
      "type": "treatment_type"
    },
    {
      "id": 8,
      "text": "chronic depression",
      "type": "medical_condition"
    },
    {
      "id": 9,
      "text": "Cognitive Behavioral Analysis System of Psychotherapy (CBASP)",
      "type": "treatment_type"
    },
    {
      "id": 10,
      "text": "Behavioral activation",
      "type": "treatment_type"
    },
    {
      "id": 11,
      "text": "Acceptance and commitment therapy",
      "type": "treatment_type"
    },
    {
      "id": 12,
      "text": "computerized CBT (CCBT)",
      "type": "treatment_type"
    },
    {
      "id": 13,
      "text": "Schema therapy",
      "type": "treatment_type"
    },
    {
      "id": 14,
      "text": "Problem-solving therapy (PST)",
      "type": "treatment_type"
    },
    {
      "id": 15,
      "text": "Marital and family therapy (MFT)",
      "type": "treatment_type"
    },
    {
      "id": 16,
      "text": "Psychodynamic therapy",
      "type": "treatment_type"
    },
    {
      "id": 17,
      "text": "patients with depression",
      "type": "patient_group"
    },
    {
      "id": 18,
      "text": "depressed patients",
      "type": "patient_group"
    },
    {
      "id": 20,
      "text": "adolescent patients with depression",
      "type": "patient_group"
    },
    {
      "id": 23,
      "text": "adolescents with depression",
      "type": "patient_group"
    },
    {
      "id": 24,
      "text": "elderly",
      "type": "patient_group"
    },
    {
      "id": 25,
      "text": "patients with mild depressive symptoms",
      "type": "patient_group"
    },
    {
      "id": 26,
      "text": "remission",
      "type": "outcome"
    },
    {
      "id": 27,
      "text": "relapses",
      "type": "outcome"
    },
    {
      "id": 30,
      "text": "effect sizes",
      "type": "outcome"
    },
    {
      "id": 31,
      "text": "antidepressants",
      "type": "medication"
    },
    {
      "id": 2,
      "text": "Psychodynamic therapy",
      "type": "treatment_type"
    },
    {
      "id": 6,
      "text": "subthreshold depression",
      "type": "medical_condition"
    },
    {
      "id": 8,
      "text": "MBCT",
      "type": "treatment_type"
    },
    {
      "id": 12,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 17,
      "text": "resistant depression",
      "type": "medical_condition"
    },
    {
      "id": 18,
      "text": "pharmacotherapy",
      "type": "treatment_type"
    },
    {
      "id": 19,
      "text": "major unipolar depression",
      "type": "medical_condition"
    },
    {
      "id": 20,
      "text": "repetitive transcranial magnetic stimulation (rTMS)",
      "type": "treatment_type"
    },
    {
      "id": 21,
      "text": "transcranial direct current stimulation (tDCS)",
      "type": "treatment_type"
    },
    {
      "id": 22,
      "text": "vagus nerve stimulation (VNS)",
      "type": "treatment_type"
    },
    {
      "id": 23,
      "text": "deep brain stimulation (DBS)",
      "type": "treatment_type"
    },
    {
      "id": 24,
      "text": "magnetic seizure therapy",
      "type": "treatment_type"
    },
    {
      "id": 28,
      "text": "placebo",
      "type": "treatment_type"
    },
    {
      "id": 29,
      "text": "patients with depression",
      "type": "patient_group"
    },
    {
      "id": 32,
      "text": "remission",
      "type": "outcome"
    },
    {
      "id": 34,
      "text": "depressive recurrence",
      "type": "outcome"
    },
    {
      "id": 35,
      "text": "clinical course",
      "type": "outcome"
    },
    {
      "id": 36,
      "text": "treatment adherence",
      "type": "outcome"
    },
    {
      "id": 38,
      "text": "quality of life",
      "type": "outcome"
    },
    {
      "id": 39,
      "text": "effectiveness",
      "type": "outcome"
    },
    {
      "id": 40,
      "text": "safety",
      "type": "outcome"
    },
    {
      "id": 42,
      "text": "complications",
      "type": "outcome"
    },
    {
      "id": 43,
      "text": "cognitive outcomes",
      "type": "outcome"
    },
    {
      "id": 45,
      "text": "side effects",
      "type": "outcome"
    },
    {
      "id": 46,
      "text": "acceptability",
      "type": "outcome"
    },
    {
      "id": 48,
      "text": "neuroplastic changes",
      "type": "outcome"
    },
    {
      "id": 49,
      "text": "eight weeks",
      "type": "quantitative_result"
    },
    {
      "id": 50,
      "text": "six to eight sessions",
      "type": "quantitative_result"
    },
    {
      "id": 4,
      "text": "10 wk",
      "type": "quantitative_result"
    },
    {
      "id": 5,
      "text": "six to 12 mo",
      "type": "quantitative_result"
    },
    {
      "id": 6,
      "text": "two years",
      "type": "quantitative_result"
    },
    {
      "id": 9,
      "text": "60%",
      "type": "quantitative_result"
    },
    {
      "id": 10,
      "text": "six months",
      "type": "quantitative_result"
    },
    {
      "id": 11,
      "text": "35%",
      "type": "quantitative_result"
    },
    {
      "id": 12,
      "text": "over 12 mo",
      "type": "quantitative_result"
    },
    {
      "id": 13,
      "text": "resistant depression",
      "type": "medical_condition"
    },
    {
      "id": 14,
      "text": "week one",
      "type": "quantitative_result"
    },
    {
      "id": 19,
      "text": "Luxtherapy (phototherapy)",
      "type": "treatment_type"
    },
    {
      "id": 20,
      "text": "depression symptoms",
      "type": "outcome"
    },
    {
      "id": 21,
      "text": "2500 Lux",
      "type": "quantitative_result"
    },
    {
      "id": 22,
      "text": "two hours per day",
      "type": "quantitative_result"
    },
    {
      "id": 23,
      "text": "10000 Lux",
      "type": "quantitative_result"
    },
    {
      "id": 24,
      "text": "half an hour per day",
      "type": "quantitative_result"
    },
    {
      "id": 25,
      "text": "6000 Lux",
      "type": "quantitative_result"
    },
    {
      "id": 26,
      "text": "1.5 h per day",
      "type": "quantitative_result"
    },
    {
      "id": 27,
      "text": "seasonal and non-seasonal depression",
      "type": "medical_condition"
    },
    {
      "id": 28,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 29,
      "text": "ECT",
      "type": "treatment_type"
    },
    {
      "id": 30,
      "text": "rTMS",
      "type": "treatment_type"
    },
    {
      "id": 31,
      "text": "tDCS",
      "type": "treatment_type"
    },
    {
      "id": 32,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 33,
      "text": "antidepressants",
      "type": "medication"
    },
    {
      "id": 34,
      "text": "psychotherapies",
      "type": "treatment_type"
    },
    {
      "id": 35,
      "text": "somatic approaches",
      "type": "treatment_type"
    },
    {
      "id": 36,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 37,
      "text": "ECT",
      "type": "treatment_type"
    },
    {
      "id": 38,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 2,
      "text": "depressed outpatients",
      "type": "patient_group"
    },
    {
      "id": 5,
      "text": "placebo",
      "type": "medication"
    },
    {
      "id": 6,
      "text": "controlled trial",
      "type": "study"
    },
    {
      "id": 8,
      "text": "Phenelzine",
      "type": "medication"
    },
    {
      "id": 9,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 11,
      "text": "meta-analytic approach",
      "type": "study"
    },
    {
      "id": 14,
      "text": "monoamine oxidase inhibitor",
      "type": "medication"
    },
    {
      "id": 15,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 18,
      "text": "mirtazapine",
      "type": "medication"
    },
    {
      "id": 20,
      "text": "STAR*D",
      "type": "study"
    },
    {
      "id": 22,
      "text": "MDD",
      "type": "medical_condition"
    },
    {
      "id": 23,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 25,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 29,
      "text": "systematic review and meta-analysis",
      "type": "study"
    },
    {
      "id": 31,
      "text": "inpatients",
      "type": "patient_group"
    },
    {
      "id": 33,
      "text": "outpatients",
      "type": "patient_group"
    },
    {
      "id": 34,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 37,
      "text": "depressed inpatients",
      "type": "patient_group"
    },
    {
      "id": 38,
      "text": "meta-analysis",
      "type": "study"
    },
    {
      "id": 43,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 46,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 47,
      "text": "depressive disorders",
      "type": "medical_condition"
    },
    {
      "id": 49,
      "text": "Evidence-based guidelines",
      "type": "study"
    },
    {
      "id": 52,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 53,
      "text": "short and long term",
      "type": "outcome"
    },
    {
      "id": 54,
      "text": "depressive states",
      "type": "medical_condition"
    },
    {
      "id": 56,
      "text": "cognitive behavioral therapies",
      "type": "treatment_type"
    },
    {
      "id": 57,
      "text": "major depressive disorder",
      "type": "medical_condition"
    },
    {
      "id": 58,
      "text": "systematic review and meta-analysis",
      "type": "study"
    },
    {
      "id": 61,
      "text": "pharmacotherapy",
      "type": "treatment_type"
    },
    {
      "id": 62,
      "text": "Cochrane Database Syst Rev",
      "type": "study"
    },
    {
      "id": 63,
      "text": "paroxetine",
      "type": "medication"
    },
    {
      "id": 64,
      "text": "tricyclic antidepressants",
      "type": "medication"
    },
    {
      "id": 65,
      "text": "major depression",
      "type": "medical_condition"
    },
    {
      "id": 66,
      "text": "meta-analysis",
      "type": "study"
    },
    {
      "id": 67,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 68,
      "text": "tolerability",
      "type": "outcome"
    },
    {
      "id": 70,
      "text": "escitalopram",
      "type": "medication"
    },
    {
      "id": 73,
      "text": "venlafaxine XR",
      "type": "medication"
    },
    {
      "id": 74,
      "text": "meta-analysis",
      "type": "study"
    },
    {
      "id": 75,
      "text": "Escitalopram",
      "type": "medication"
    },
    {
      "id": 76,
      "text": "major depressive disorder",
      "type": "medical_condition"
    },
    {
      "id": 77,
      "text": "selective serotonin reuptake inhibitors",
      "type": "medication"
    },
    {
      "id": 79,
      "text": "SSRIs",
      "type": "medication"
    },
    {
      "id": 81,
      "text": "major depressive disorder",
      "type": "medical_condition"
    },
    {
      "id": 83,
      "text": "duloxetine",
      "type": "medication"
    },
    {
      "id": 84,
      "text": "selective serotonin reuptake inhibitors",
      "type": "medication"
    },
    {
      "id": 9,
      "text": "multiple-treatments meta-analysis",
      "type": "study"
    },
    {
      "id": 12,
      "text": "randomized controlled trial",
      "type": "study"
    },
    {
      "id": 30,
      "text": "major depressive disorder",
      "type": "medical_condition"
    },
    {
      "id": 41,
      "text": "major depressive disorder",
      "type": "medical_condition"
    },
    {
      "id": 45,
      "text": "treatment-resistant depression",
      "type": "medical_condition"
    },
    {
      "id": 53,
      "text": "Mood Disorders",
      "type": "medical_condition"
    },
    {
      "id": 4,
      "text": "depression",
      "type": "medical_condition"
    },
    {
      "id": 6,
      "text": "Glutamatergic Agents",
      "type": "medication"
    },
    {
      "id": 7,
      "text": "Riluzole",
      "type": "medication"
    },
    {
      "id": 11,
      "text": "major depressive disorder",
      "type": "medical_condition"
    },
    {
      "id": 17,
      "text": "schema therapy",
      "type": "treatment_type"
    },
    {
      "id": 21,
      "text": "Depression",
      "type": "medical_condition"
    },
    {
      "id": 23,
      "text": "efficacy",
      "type": "outcome"
    },
    {
      "id": 24,
      "text": "safety",
      "type": "outcome"
    },
    {
      "id": 26,
      "text": "healthy controls",
      "type": "patient_group"
    },
    {
      "id": 27,
      "text": "adults",
      "type": "patient_group"
    },
    {
      "id": 28,
      "text": "people aged 65 years and over",
      "type": "patient_group"
    },
    {
      "id": 3,
      "text": "older, primary care patients",
      "type": "patient_group"
    },
    {
      "id": 22,
      "text": "randomized controlled trial",
      "type": "study"
    },
    {
      "id": 27,
      "text": "Mindfulness-based cognitive therapy",
      "type": "treatment_type"
    },
    {
      "id": 29,
      "text": "MDD",
      "type": "medical_condition"
    },
    {
      "id": 33,
      "text": "exercise",
      "type": "treatment_type"
    },
    {
      "id": 36,
      "text": "exercise",
      "type": "treatment_type"
    },
    {
      "id": 40,
      "text": "Psychotherapy",
      "type": "treatment_type"
    },
    {
      "id": 42,
      "text": "Brief psychotherapy",
      "type": "treatment_type"
    },
    {
      "id": 44,
      "text": "Electroconvulsive therapy",
      "type": "treatment_type"
    },
    {
      "id": 46,
      "text": "Electroconvulsive Therapy",
      "type": "treatment_type"
    },
    {
      "id": 48,
      "text": "Electroconvulsive therapy",
      "type": "treatment_type"
    },
    {
      "id": 50,
      "text": "Electroconvulsive therapy",
      "type": "treatment_type"
    },
    {
      "id": 51,
      "text": "mortality rate",
      "type": "outcome"
    },
    {
      "id": 52,
      "text": "Electroconvulsive therapy",
      "type": "treatment_type"
    },
    {
      "id": 54,
      "text": "Electroconvulsive therapy",
      "type": "treatment_type"
    },
    {
      "id": 57,
      "text": "Electroconvulsive Therapy",
      "type": "treatment_type"
    },
    {
      "id": 58,
      "text": "Dementia",
      "type": "medical_condition"
    },
    {
      "id": 59,
      "text": "ECT",
      "type": "treatment_type"
    },
    {
      "id": 60,
      "text": "pregnancy",
      "type": "patient_group"
    },
    {
      "id": 62,
      "text": "suicide prevention",
      "type": "outcome"
    },
    {
      "id": 63,
      "text": "ECT",
      "type": "treatment_type"
    },
    {
      "id": 64,
      "text": "movement disorders",
      "type": "medical_condition"
    },
    {
      "id": 65,
      "text": "Electroconvulsive therapy",
      "type": "treatment_type"
    },
    {
      "id": 66,
      "text": "pregnancy",
      "type": "patient_group"
    },
    {
      "id": 67,
      "text": "major depression",
      "type": "medical_condition"
    },
    {
      "id": 18,
      "text": "treatment-resistant depression",
      "type": "medical_condition"
    },
    {
      "id": 21,
      "text": "Volume increase in the dentate gyrus",
      "type": "outcome"
    },
    {
      "id": 22,
      "text": "relapse",
      "type": "outcome"
    },
    {
      "id": 28,
      "text": "7T",
      "type": "measure"
    },
    {
      "id": 30,
      "text": "systematic review and network meta-analysis",
      "type": "study"
    },
    {
      "id": 31,
      "text": "individual patient data meta-analysis",
      "type": "study"
    },
    {
      "id": 32,
      "text": "Pilot trial",
      "type": "study"
    },
    {
      "id": 33,
      "text": "randomized, placebo-controlled trials",
      "type": "study"
    },
    {
      "id": 34,
      "text": "randomized to different amounts of electrical charge",
      "type": "study"
    },
    {
      "id": 35,
      "text": "different amounts of electrical charge",
      "type": "dosage"
    },
    {
      "id": 3,
      "text": "randomized, controlled acute phase trial",
      "type": "study"
    },
    {
      "id": 5,
      "text": "European study",
      "type": "study"
    },
    {
      "id": 16,
      "text": "winter depression",
      "type": "medical_condition"
    },
    {
      "id": 21,
      "text": "17-item Hamilton Depression Rating Scale (HAM-D)",
      "type": "measure"
    },
    {
      "id": 27,
      "text": "286",
      "type": "quantitative_result"
    },
    {
      "id": 28,
      "text": "53.2%",
      "type": "quantitative_result"
    },
    {
      "id": 29,
      "text": "1292",
      "type": "quantitative_result"
    },
    {
      "id": 30,
      "text": "7",
      "type": "quantitative_result"
    },
    {
      "id": 5,
      "text": "HAM-D",
      "type": "measure"
    },
    {
      "id": 6,
      "text": "QIDS-C",
      "type": "measure"
    },
    {
      "id": 7,
      "text": "QIDS-SR",
      "type": "measure"
    },
    {
      "id": 11,
      "text": "patients",
      "type": "patient_group"
    },
    {
      "id": 13,
      "text": "20 mg/day",
      "type": "dosage"
    },
    {
      "id": 14,
      "text": "40 mg/day",
      "type": "dosage"
    },
    {
      "id": 15,
      "text": "60 mg/day",
      "type": "dosage"
    },
    {
      "id": 16,
      "text": "N=2,876",
      "type": "quantitative_result"
    },
    {
      "id": 17,
      "text": "≤5",
      "type": "quantitative_result"
    },
    {
      "id": 18,
      "text": "≥9",
      "type": "quantitative_result"
    },
    {
      "id": 19,
      "text": ">5",
      "type": "quantitative_result"
    },
    {
      "id": 20,
      "text": "≥7",
      "type": "quantitative_result"
    },
    {
      "id": 4,
      "text": "remission",
      "type": "outcome"
    },
    {
      "id": 5,
      "text": "response",
      "type": "outcome"
    },
    {
      "id": 7,
      "text": "patients with anxious depression",
      "type": "patient_group"
    },
    {
      "id": 10,
      "text": "HAM-D",
      "type": "measure"
    },
    {
      "id": 11,
      "text": "QIDS-SR",
      "type": "measure"
    },
    {
      "id": 13,
      "text": "≤5",
      "type": "quantitative_result"
    },
    {
      "id": 15,
      "text": "0.05",
      "type": "quantitative_result"
    },
    {
      "id": 21,
      "text": "mg/day",
      "type": "dosage"
    },
    {
      "id": 22,
      "text": "<20",
      "type": "dosage"
    },
    {
      "id": 23,
      "text": "20–39",
      "type": "dosage"
    },
    {
      "id": 24,
      "text": "40–49",
      "type": "dosage"
    },
    {
      "id": 25,
      "text": "≥50",
      "type": "dosage"
    },
    {
      "id": 26,
      "text": "weeks",
      "type": "dosage"
    },
    {
      "id": 27,
      "text": "<4",
      "type": "dosage"
    },
    {
      "id": 28,
      "text": "≥4 but <8",
      "type": "dosage"
    },
    {
      "id": 29,
      "text": "≥8",
      "type": "dosage"
    },
    {
      "id": 31,
      "text": "0.0602",
      "type": "quantitative_result"
    },
    {
      "id": 32,
      "text": "25",
      "type": "quantitative_result"
    },
    {
      "id": 33,
      "text": "1.9",
      "type": "quantitative_result"
    },
    {
      "id": 34,
      "text": "38",
      "type": "quantitative_result"
    },
    {
      "id": 35,
      "text": "2.5",
      "type": "quantitative_result"
    },
    {
      "id": 36,
      "text": "63",
      "type": "quantitative_result"
    },
    {
      "id": 37,
      "text": "2.2",
      "type": "quantitative_result"
    },
    {
      "id": 38,
      "text": "342",
      "type": "quantitative_result"
    },
    {
      "id": 39,
      "text": "25.5",
      "type": "quantitative_result"
    },
    {
      "id": 40,
      "text": "352",
      "type": "quantitative_result"
    },
    {
      "id": 41,
      "text": "23.1",
      "type": "quantitative_result"
    },
    {
      "id": 42,
      "text": "694",
      "type": "quantitative_result"
    },
    {
      "id": 43,
      "text": "24.2",
      "type": "quantitative_result"
    },
    {
      "id": 44,
      "text": "407",
      "type": "quantitative_result"
    },
    {
      "id": 45,
      "text": "30.3",
      "type": "quantitative_result"
    },
    {
      "id": 46,
      "text": "455",
      "type": "quantitative_result"
    },
    {
      "id": 47,
      "text": "29.8",
      "type": "quantitative_result"
    },
    {
      "id": 48,
      "text": "862",
      "type": "quantitative_result"
    },
    {
      "id": 51,
      "text": "42.3",
      "type": "quantitative_result"
    },
    {
      "id": 52,
      "text": "681",
      "type": "quantitative_result"
    },
    {
      "id": 53,
      "text": "44.6",
      "type": "quantitative_result"
    },
    {
      "id": 54,
      "text": "1,250",
      "type": "quantitative_result"
    },
    {
      "id": 55,
      "text": "43.5",
      "type": "quantitative_result"
    },
    {
      "id": 76,
      "text": "615",
      "type": "quantitative_result"
    },
    {
      "id": 77,
      "text": "40.3",
      "type": "quantitative_result"
    },
    {
      "id": 78,
      "text": "1,123",
      "type": "quantitative_result"
    },
    {
      "id": 79,
      "text": "39.1",
      "type": "quantitative_result"
    },
    {
      "id": 80,
      "text": "134",
      "type": "quantitative_result"
    },
    {
      "id": 81,
      "text": "10.0",
      "type": "quantitative_result"
    },
    {
      "id": 82,
      "text": "189",
      "type": "quantitative_result"
    },
    {
      "id": 83,
      "text": "12.4",
      "type": "quantitative_result"
    },
    {
      "id": 84,
      "text": "323",
      "type": "quantitative_result"
    },
    {
      "id": 85,
      "text": "11.2",
      "type": "quantitative_result"
    },
    {
      "id": 86,
      "text": "191",
      "type": "quantitative_result"
    },
    {
      "id": 87,
      "text": "14.2",
      "type": "quantitative_result"
    },
    {
      "id": 88,
      "text": "294",
      "type": "quantitative_result"
    },
    {
      "id": 89,
      "text": "19.2",
      "type": "quantitative_result"
    },
    {
      "id": 90,
      "text": "485",
      "type": "quantitative_result"
    },
    {
      "id": 91,
      "text": "16.9",
      "type": "quantitative_result"
    },
    {
      "id": 92,
      "text": "1,021",
      "type": "quantitative_result"
    },
    {
      "id": 93,
      "text": "75.8",
      "type": "quantitative_result"
    },
    {
      "id": 94,
      "text": "1,047",
      "type": "quantitative_result"
    },
    {
      "id": 95,
      "text": "68.4",
      "type": "quantitative_result"
    },
    {
      "id": 96,
      "text": "2,068",
      "type": "quantitative_result"
    },
    {
      "id": 97,
      "text": "71.9",
      "type": "quantitative_result"
    },
    {
      "id": 98,
      "text": "4.9",
      "type": "quantitative_result"
    },
    {
      "id": 99,
      "text": "1.5",
      "type": "quantitative_result"
    },
    {
      "id": 100,
      "text": "4.7",
      "type": "quantitative_result"
    },
    {
      "id": 101,
      "text": "4.8",
      "type": "quantitative_result"
    },
    {
      "id": 102,
      "text": "2.3",
      "type": "quantitative_result"
    },
    {
      "id": 103,
      "text": "1.0",
      "type": "quantitative_result"
    },
    {
      "id": 104,
      "text": "2.4",
      "type": "quantitative_result"
    },
    {
      "id": 105,
      "text": "1.2",
      "type": "quantitative_result"
    },
    {
      "id": 106,
      "text": "2.3",
      "type": "quantitative_result"
    },
    {
      "id": 107,
      "text": "1.1",
      "type": "quantitative_result"
    },
    {
      "id": 108,
      "text": "10.3",
      "type": "quantitative_result"
    },
    {
      "id": 109,
      "text": "4.0",
      "type": "quantitative_result"
    },
    {
      "id": 110,
      "text": "9.8",
      "type": "quantitative_result"
    },
    {
      "id": 111,
      "text": "4.3",
      "type": "quantitative_result"
    },
    {
      "id": 112,
      "text": "10",
      "type": "quantitative_result"
    },
    {
      "id": 113,
      "text": "4.2",
      "type": "quantitative_result"
    },
    {
      "id": 114,
      "text": "5.5",
      "type": "quantitative_result"
    },
    {
      "id": 115,
      "text": "4.2",
      "type": "quantitative_result"
    },
    {
      "id": 116,
      "text": "4.7",
      "type": "quantitative_result"
    },
    {
      "id": 117,
      "text": "3.8",
      "type": "quantitative_result"
    },
    {
      "id": 118,
      "text": "5.1",
      "type": "quantitative_result"
    },
    {
      "id": 119,
      "text": "4.0",
      "type": "quantitative_result"
    },
    {
      "id": 120,
      "text": "<0.0001",
      "type": "quantitative_result"
    },
    {
      "id": 121,
      "text": "<0.0001",
      "type": "quantitative_result"
    },
    {
      "id": 122,
      "text": "0.2124",
      "type": "quantitative_result"
    },
    {
      "id": 123,
      "text": "0.0002",
      "type": "quantitative_result"
    },
    {
      "id": 124,
      "text": "<0.0001",
      "type": "quantitative_result"
    },
    {
      "id": 86,
      "text": "major depressive disorder",
      "type": "medical_condition"
    },
    {
      "id": 87,
      "text": "bupropion",
      "type": "medication"
    },
    {
      "id": 88,
      "text": "sertraline",
      "type": "medication"
    },
    {
      "id": 89,
      "text": "venlafaxine",
      "type": "medication"
    },
    {
      "id": 90,
      "text": "buspirone",
      "type": "medication"
    },
    {
      "id": 91,
      "text": "adult outpatients",
      "type": "patient_group"
    },
    {
      "id": 92,
      "text": "400 mg",
      "type": "dosage"
    },
    {
      "id": 93,
      "text": "200 mg",
      "type": "dosage"
    },
    {
      "id": 94,
      "text": "375 mg",
      "type": "dosage"
    },
    {
      "id": 95,
      "text": "400 mg",
      "type": "dosage"
    },
    {
      "id": 96,
      "text": "60 mg",
      "type": "dosage"
    },
    {
      "id": 19,
      "text": "poorer treatment outcome",
      "type": "outcome"
    },
    {
      "id": 26,
      "text": "STAR*D",
      "type": "study"
    },
    {
      "id": 27,
      "text": "STAR*D",
      "type": "study"
    },
    {
      "id": 28,
      "text": "STAR*D",
      "type": "study"
    },
    {
      "id": 30,
      "text": "HAM-D",
      "type": "measure"
    },
    {
      "id": 31,
      "text": "HAM-D",
      "type": "measure"
    },
    {
      "id": 32,
      "text": "QIDS-SR",
      "type": "measure"
    },
    {
      "id": 15,
      "text": "45-year-old married woman",
      "type": "patient_group"
    },
    {
      "id": 16,
      "text": "STAR*D",
      "type": "study"
    },
    {
      "id": 21,
      "text": "Sequenced treatment alternatives to relieve depression (STAR*D)",
      "type": "study"
    },
    {
      "id": 30,
      "text": "outpatients",
      "type": "patient_group"
    },
    {
      "id": 1,
      "text": "STAR*D",
      "type": "study"
    },
    {
      "id": 2,
      "text": "side effects",
      "type": "outcome"
    },
    {
      "id": 4,
      "text": "Sequenced Treatment Alternatives to Relieve Depression study",
      "type": "study"
    }
  ],
  "relationships": [
    {
      "head": 2,
      "tail": 10,
      "type": "treats",
      "evidence": "While selective serotonin reuptake inhibitors (SSRIs) remain the gold-standard treatment for depression, new antidepressants are always being developed and tested."
    },
    {
      "head": 3,
      "tail": 10,
      "type": "treats",
      "evidence": "While selective serotonin reuptake inhibitors (SSRIs) remain the gold-standard treatment for depression, new antidepressants are always being developed and tested."
    },
    {
      "head": 4,
      "tail": 10,
      "type": "treats",
      "evidence": "Depression-focused psychotherapy is the second most common option for helping patients overcome the acute phase, maintain remission, and prevent relapses."
    },
    {
      "head": 5,
      "tail": 10,
      "type": "treats",
      "evidence": "Electrocon- vulsive therapy is the most effective somatic therapy for depression in some specific situations; meanwhile, other methods have limits, and their specific indications are still being studied."
    },
    {
      "head": 6,
      "tail": 10,
      "type": "treats",
      "evidence": "Electrocon- vulsive therapy is the most effective somatic therapy for depression in some specific situations; meanwhile, other methods have limits, and their specific indications are still being studied."
    },
    {
      "head": 2,
      "tail": 7,
      "type": "has_outcome",
      "evidence": "While selective serotonin reuptake inhibitors (SSRIs) remain the gold-standard treatment for depression, new antidepressants are always being developed and tested. The ultimate goal is to discover a molecule that exhibits quick effectiveness with as few side effects as possible."
    },
    {
      "head": 2,
      "tail": 8,
      "type": "has_outcome",
      "evidence": "While selective serotonin reuptake inhibitors (SSRIs) remain the gold-standard treatment for depression, new antidepressants are always being developed and tested. The ultimate goal is to discover a molecule that exhibits quick effectiveness with as few side effects as possible."
    },
    {
      "head": 4,
      "tail": 7,
      "type": "has_outcome",
      "evidence": "Depression-focused psychotherapy is the second most common option for helping patients overcome the acute phase, maintain remission, and prevent relapses."
    },
    {
      "head": 4,
      "tail": 9,
      "type": "has_outcome",
      "evidence": "Depression-focused psychotherapy is the second most common option for helping patients overcome the acute phase, maintain remission, and prevent relapses."
    },
    {
      "head": 12,
      "tail": 13,
      "type": "has_outcome",
      "evidence": "Due to their irreversible inhibition of monoamine oxidase, MOAIs have numerous side effects, such as hepatotoxicity and hypertensive crises, that can lead to lethal intracranial hemorrhages."
    },
    {
      "head": 12,
      "tail": 14,
      "type": "has_outcome",
      "evidence": "Due to their irreversible inhibition of monoamine oxidase, MOAIs have numerous side effects, such as hepatotoxicity and hypertensive crises, that can lead to lethal intracranial hemorrhages."
    },
    {
      "head": 12,
      "tail": 15,
      "type": "has_outcome",
      "evidence": "Due to their irreversible inhibition of monoamine oxidase, MOAIs have numerous side effects, such as hepatotoxicity and hypertensive crises, that can lead to lethal intracranial hemorrhages."
    },
    {
      "head": 1,
      "tail": 2,
      "type": "treats",
      "evidence": "Furthermore, MAOIs have demonstrated specific efficacy in treating depression with atypical features, such as reactive moods, reverse neuro-vegetative symptoms, and sensitivity to rejection[12]."
    },
    {
      "head": 1,
      "tail": 3,
      "type": "has_outcome",
      "evidence": "However, considering MAOIs’ drug interactions, dietary restrictions, and potentially dangerous side effects, they are now almost exclusively prescribed for patients who have not responded to several other pharma- cotherapies, including TCAs[9]."
    },
    {
      "head": 1,
      "tail": 11,
      "type": "has_outcome",
      "evidence": "MAOIs’ effectiveness is still unclear for treating depression in patients who are resistant to multiple sequential trials with SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs)[14]."
    },
    {
      "head": 1,
      "tail": 7,
      "type": "treats",
      "evidence": "MAOIs’ effectiveness is still unclear for treating depression in patients who are resistant to multiple sequential trials with SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs)[14]."
    },
    {
      "head": 6,
      "tail": 2,
      "type": "treats",
      "evidence": "MAOIs are also a potential therapeutic option when ECT is contraindicated[13]."
    },
    {
      "head": 12,
      "tail": 14,
      "type": "treats",
      "evidence": "TCAs-such as amitriptyline, nortriptyline, protrip- tyline, imipramine, desipramine, doxepin, and trimipramine-are about as effective as other classes of antidepressants-including SSRIs, SNRIs, and MAOIs-in treating major depression[18,19]."
    },
    {
      "head": 12,
      "tail": 18,
      "type": "has_outcome",
      "evidence": "However, some TCAs can be more effective than SSRIs when used to treat hospit- alized patients[20]. This efficacy can be explained by the superiority of TCAs over SSRIs for patients with severe major depressive disorder (MDD) symptoms who require hospitalization[21-24]."
    },
    {
      "head": 23,
      "tail": 24,
      "type": "treats",
      "evidence": "In December 1987, a series of clinical studies confirmed that an SSRI called fluoxetine was as effective as TCAs for treating depression while causing fewer adverse effects [26]."
    },
    {
      "head": 23,
      "tail": 25,
      "type": "has_outcome",
      "evidence": "In December 1987, a series of clinical studies confirmed that an SSRI called fluoxetine was as effective as TCAs for treating depression while causing fewer adverse effects [26]."
    },
    {
      "head": 30,
      "tail": 28,
      "type": "has_outcome",
      "evidence": "They have elicited different tolerance rates and side effects-mostly sexual and digestive (nausea and loss of appetite), as well as irritability, anxiety, insomnia, and headaches[27]."
    },
    {
      "head": 30,
      "tail": 29,
      "type": "has_outcome",
      "evidence": "They have elicited different tolerance rates and side effects-mostly sexual and digestive (nausea and loss of appetite), as well as irritability, anxiety, insomnia, and headaches[27]."
    },
    {
      "head": 30,
      "tail": 31,
      "type": "has_outcome",
      "evidence": "In most systematic reviews and meta-analyses, SSRIs have demonstrated comparable efficacy to TCAs[18,19,29], and there is no significant evidence indicating the superiority of any other class or agent over SSRIs[29-31]."
    },
    {
      "head": 30,
      "tail": 35,
      "type": "treats",
      "evidence": "Therefore, most guidelines currently recommend SSRIs as the first-line treatment for patients with major depression[25]."
    },
    {
      "head": 36,
      "tail": 37,
      "type": "has_outcome",
      "evidence": "Other monoamine (norepinephrine, serotonin, and dopamine) neurotransmitter reuptake inhibitors called SNRIs emerged during the 1990s to protect patients against the adverse effects of SSRIs[35]."
    },
    {
      "head": 39,
      "tail": 40,
      "type": "treats",
      "evidence": "Clinical guidelines commonly recommend prescribing SNRI to patients who do not respond to SSRIs[25]."
    },
    {
      "head": 43,
      "tail": 44,
      "type": "has_outcome",
      "evidence": "In individual studies, venlafaxine and duloxetine are generally considered effective as SSRIs[36]. Also, venlafaxine’s efficacy is comparable to that of TCAs[37,38]."
    },
    {
      "head": 43,
      "tail": 45,
      "type": "treats",
      "evidence": "Also, venlafaxine’s efficacy is comparable to that of TCAs[37,38]."
    },
    {
      "head": 46,
      "tail": 47,
      "type": "has_outcome",
      "evidence": "According to some meta-analyses, reboxetine (a selective noradrenaline reuptake inhibitor) seems less efficacious than SSRIs[39]."
    },
    {
      "head": 46,
      "tail": 49,
      "type": "has_outcome",
      "evidence": "However, these findings could be due to the relatively poor tolerance of reboxetine[40]."
    },
    {
      "head": 50,
      "tail": 51,
      "type": "treats",
      "evidence": "Trazodone is the oldest medication of the so-called “other antidepressants” group that is still in wide use[41,42]. It has been shown to be an effective antidepressant in placebo-controlled research."
    },
    {
      "head": 50,
      "tail": 53,
      "type": "treats",
      "evidence": "However, in contemporary practice, it is much more likely to be used in low doses as a sedative-hypnotic than as an antidepressant[41,42]."
    },
    {
      "head": 54,
      "tail": 55,
      "type": "has_outcome",
      "evidence": "Its efficacy and overall tolerability are comparable to those of SSRIs, as indicated by comparative trials[43]."
    },
    {
      "head": 54,
      "tail": 56,
      "type": "has_outcome",
      "evidence": "Its efficacy and overall tolerability are comparable to those of SSRIs, as indicated by comparative trials[43]."
    },
    {
      "head": 54,
      "tail": 57,
      "type": "treats",
      "evidence": "Its efficacy and overall tolerability are comparable to those of SSRIs, as indicated by comparative trials[43]."
    },
    {
      "head": 54,
      "tail": 58,
      "type": "has_outcome",
      "evidence": "However, its use is associated with rare (but fatal) cases of clinical idiosyncratic hepatotoxicity[44]."
    },
    {
      "head": 59,
      "tail": 60,
      "type": "treats",
      "evidence": "It appears to have a more activating profile than SSRIs that are modestly superior to bupropion in patients with MDD[46]."
    },
    {
      "head": 59,
      "tail": 61,
      "type": "has_outcome",
      "evidence": "It appears to have a more activating profile than SSRIs that are modestly superior to bupropion in patients with MDD[46]."
    },
    {
      "head": 59,
      "tail": 63,
      "type": "treats",
      "evidence": "However, for individuals with low to moderate levels of anxiety, the efficacy of bupropion in treating MDD is comparable to that of SSRIs[46]."
    },
    {
      "head": 59,
      "tail": 64,
      "type": "has_outcome",
      "evidence": "However, for individuals with low to moderate levels of anxiety, the efficacy of bupropion in treating MDD is comparable to that of SSRIs[46]."
    },
    {
      "head": 59,
      "tail": 66,
      "type": "has_outcome",
      "evidence": "Moreover, bupropion has a better tolerability profile than SSRIs, with minimal weight gain (or even leading to weight loss)[46]."
    },
    {
      "head": 68,
      "tail": 69,
      "type": "treats",
      "evidence": "Mirtazapine is about as effective as SSRIs[48]."
    },
    {
      "head": 72,
      "tail": 70,
      "type": "has_outcome",
      "evidence": "However, they appear to produce less sexual dysfunction and, in the specific case of vortioxetine, have particular benefits in depression-related cognitive impairment[49]."
    },
    {
      "head": 72,
      "tail": 73,
      "type": "has_outcome",
      "evidence": "Indeed, vortioxetine is a very recent antidepressant with a multimodal mechanism that is thought to have a high affinity for serotonin transporters and 5-HT3, 5HT1A, 5HT7 receptors. Such a specific profile seems to indicate a level of efficacy to other antidepressants with a specific action on cognitive impairments[50,51]."
    },
    {
      "head": 74,
      "tail": 75,
      "type": "has_outcome",
      "evidence": "In conclusion, no significant differences have been found between different classes of antidepressants in terms of their efficacy[52], though some drugs show some weak- to-moderate evidence indicating they are more effective than some other drugs[53]."
    },
    {
      "head": 76,
      "tail": 77,
      "type": "has_outcome",
      "evidence": "Concerning the acceptability of these drugs, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine have been deemed more tolerable than other antide- pressants, whereas amitriptyline, clomipramine, duloxetine, fluvoxamine, trazodone, and venlafaxine had the highest dropout rates[53] because of their more frequent and severe side effects."
    },
    {
      "head": 78,
      "tail": 79,
      "type": "has_outcome",
      "evidence": "Concerning the acceptability of these drugs, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine have been deemed more tolerable than other antide- pressants, whereas amitriptyline, clomipramine, duloxetine, fluvoxamine, trazodone, and venlafaxine had the highest dropout rates[53] because of their more frequent and severe side effects."
    },
    {
      "head": 78,
      "tail": 80,
      "type": "has_outcome",
      "evidence": "Concerning the acceptability of these drugs, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine have been deemed more tolerable than other antide- pressants, whereas amitriptyline, clomipramine, duloxetine, fluvoxamine, trazodone, and venlafaxine had the highest dropout rates[53] because of their more frequent and severe side effects."
    },
    {
      "head": 81,
      "tail": 82,
      "type": "measured_by",
      "evidence": "Nausea and vomiting were the most common reasons for treatment discontinuation; sexual dysfunction, sedation, priapism, and cardiotoxicity were also reported[31,41]."
    },
    {
      "head": 83,
      "tail": 82,
      "type": "measured_by",
      "evidence": "Nausea and vomiting were the most common reasons for treatment discontinuation; sexual dysfunction, sedation, priapism, and cardiotoxicity were also reported[31,41]."
    },
    {
      "head": 84,
      "tail": 82,
      "type": "measured_by",
      "evidence": "Nausea and vomiting were the most common reasons for treatment discontinuation; sexual dysfunction, sedation, priapism, and cardiotoxicity were also reported[31,41]."
    },
    {
      "head": 85,
      "tail": 82,
      "type": "measured_by",
      "evidence": "Nausea and vomiting were the most common reasons for treatment discontinuation; sexual dysfunction, sedation, priapism, and cardiotoxicity were also reported[31,41]."
    },
    {
      "head": 86,
      "tail": 82,
      "type": "measured_by",
      "evidence": "Nausea and vomiting were the most common reasons for treatment discontinuation; sexual dysfunction, sedation, priapism, and cardiotoxicity were also reported[31,41]."
    },
    {
      "head": 4,
      "tail": 1,
      "type": "treats",
      "evidence": "In intravenous sub-anesthetic doses, ketamine has very quick effects on resistant unipolar (and, possibly, bipolar) depression and acute suicidal ideation[54,55]."
    },
    {
      "head": 4,
      "tail": 2,
      "type": "treats",
      "evidence": "In intravenous sub-anesthetic doses, ketamine has very quick effects on resistant unipolar (and, possibly, bipolar) depression and acute suicidal ideation[54,55]."
    },
    {
      "head": 4,
      "tail": 3,
      "type": "treats",
      "evidence": "In intravenous sub-anesthetic doses, ketamine has very quick effects on resistant unipolar (and, possibly, bipolar) depression and acute suicidal ideation[54,55]."
    },
    {
      "head": 4,
      "tail": 6,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 7,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 8,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 9,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 10,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 11,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 13,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 14,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 15,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 16,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 17,
      "type": "has_outcome",
      "evidence": "Common adverse effects of ketamine include dizziness, neurotoxicity, cognitive dysfunction, blurred vision, psychosis, dissociation, urological dysfunction, restlessness, headache, nausea, vomiting, and cardiovascular symptoms[58]."
    },
    {
      "head": 4,
      "tail": 18,
      "type": "has_outcome",
      "evidence": "Such adverse effects tend to be brief in acute, low-dose treatments[36], whereas prolonged exposure may predispose patients to neurotoxicity and drug dependence[56]."
    },
    {
      "head": 4,
      "tail": 7,
      "type": "has_outcome",
      "evidence": "Such adverse effects tend to be brief in acute, low-dose treatments[36], whereas prolonged exposure may predispose patients to neurotoxicity and drug dependence[56]."
    },
    {
      "head": 4,
      "tail": 5,
      "type": "treats",
      "evidence": "A few reports are have cited oral and intranasal formulations of ketamine for treatment- resistant depression[56,57], but there is still no data about the potential link between the onset of action and the route of administration."
    },
    {
      "head": 21,
      "tail": 5,
      "type": "treats",
      "evidence": "It was approved by the United States Food and Drug Administration in March 2019 for treatment-resistant depression."
    },
    {
      "head": 21,
      "tail": 18,
      "type": "has_outcome",
      "evidence": "In addition, regarding the potential risk of abuse, esketamine use must be carefully monitored[63-65]."
    },
    {
      "head": 32,
      "tail": 31,
      "type": "treats",
      "evidence": "Psychotherapeutic interventions are widely used to treat and prevent most psychiatric disorders. Such interventions are common in cases of depression, psychosocial difficulties, interpersonal problems, and intra-psychic conflicts."
    },
    {
      "head": 34,
      "tail": 56,
      "type": "reports",
      "evidence": "Product Date of FDA1 approval Contributions Disadvantages Confirmed the role of monoaminergic transmission in depression Drug interactions, dietary restrictions MAOI2 Iproniazid 1958"
    },
    {
      "head": 35,
      "tail": 57,
      "type": "reports",
      "evidence": "Imipramine 1959"
    },
    {
      "head": 37,
      "tail": 58,
      "type": "reports",
      "evidence": "Nortriptyline 1992"
    },
    {
      "head": 38,
      "tail": 59,
      "type": "reports",
      "evidence": "Amitriptyline 1961"
    },
    {
      "head": 41,
      "tail": 60,
      "type": "reports",
      "evidence": "Fluoxetine 1987"
    },
    {
      "head": 42,
      "tail": 61,
      "type": "reports",
      "evidence": "Citalopram 1998"
    },
    {
      "head": 43,
      "tail": 62,
      "type": "reports",
      "evidence": "Fluvoxamine 2007"
    },
    {
      "head": 44,
      "tail": 63,
      "type": "reports",
      "evidence": "Paroxetine 1992"
    },
    {
      "head": 45,
      "tail": 64,
      "type": "reports",
      "evidence": "Escitalopram 2002"
    },
    {
      "head": 46,
      "tail": 65,
      "type": "reports",
      "evidence": "Sertraline 1999"
    },
    {
      "head": 47,
      "tail": 66,
      "type": "reports",
      "evidence": "Venlafaxine 2008"
    },
    {
      "head": 48,
      "tail": 67,
      "type": "reports",
      "evidence": "Duloxetine 2004"
    },
    {
      "head": 50,
      "tail": 68,
      "type": "reports",
      "evidence": "Trazodone 1981"
    },
    {
      "head": 51,
      "tail": 69,
      "type": "reports",
      "evidence": "Nefazodone 2003"
    },
    {
      "head": 52,
      "tail": 70,
      "type": "reports",
      "evidence": "Bupropion 2003"
    },
    {
      "head": 53,
      "tail": 71,
      "type": "reports",
      "evidence": "Vortioxetine 2013"
    },
    {
      "head": 54,
      "tail": 72,
      "type": "reports",
      "evidence": "Vilazodone 2011"
    },
    {
      "head": 55,
      "tail": 73,
      "type": "reports",
      "evidence": "Mirtazapine 1997"
    },
    {
      "head": 4,
      "tail": 74,
      "type": "reports",
      "evidence": "Ketamine Not approved Rapid effects on resistant depression and acute suicidal ideation Short antidepressant effect. Possible neurotoxicity and drug dependence"
    },
    {
      "head": 21,
      "tail": 74,
      "type": "reports",
      "evidence": "Esketamine 2019 Treatment-resistant depression. Greater affinity for NMDA receptor than ketamine Potential risk of abuse. Lack of hindsight"
    },
    {
      "head": 20,
      "tail": 75,
      "type": "reports",
      "evidence": "Research on the S-enantiomer of ketamine (S-ketamine, or esketamine, especially intranasal) could also be valuable, as it has a 3 to 4 times greater affinity than ketamine for the N-methyl-D-aspartate (NMDA) receptor[40]."
    },
    {
      "head": 3,
      "tail": 1,
      "type": "treats",
      "evidence": "Thus, CBT is a well- known effective treatment method for MDD[78] and has been recommended in most Karrouri R et al. MDD: Validated treatments and future challenges WJCC https://www.wjgnet.com 9356 November 6, 2021 Volume 9 Issue 31"
    },
    {
      "head": 4,
      "tail": 1,
      "type": "treats",
      "evidence": "IPT, like CBT, is a first-line treatment for mild to moderate major depressive episodes in adults; it is also a well- established intervention for adolescents with depression[25]."
    },
    {
      "head": 3,
      "tail": 26,
      "type": "has_outcome",
      "evidence": "However, when psychotherapy has been effective during the initial phases of a depressive episode, it should be continued to maintain remission and prevent relapses while reducing the frequency of sessions [25,75,76]."
    },
    {
      "head": 3,
      "tail": 27,
      "type": "has_outcome",
      "evidence": "However, when psychotherapy has been effective during the initial phases of a depressive episode, it should be continued to maintain remission and prevent relapses while reducing the frequency of sessions [25,75,76]."
    },
    {
      "head": 11,
      "tail": 28,
      "type": "has_outcome",
      "evidence": "It appears to be effective in reducing depressive symptoms and preventing relapses[77,84]."
    },
    {
      "head": 11,
      "tail": 27,
      "type": "has_outcome",
      "evidence": "It appears to be effective in reducing depressive symptoms and preventing relapses[77,84]."
    },
    {
      "head": 14,
      "tail": 30,
      "type": "has_outcome",
      "evidence": "Despite its small effect sizes, PST is comparable to other psychotherapeutic methods used to treat depression[88,90]."
    },
    {
      "head": 3,
      "tail": 29,
      "type": "has_outcome",
      "evidence": "However, the effectiveness of CBT depends on patient’s capacity to observe and change their own beliefs and behaviors."
    },
    {
      "head": 13,
      "tail": 29,
      "type": "has_outcome",
      "evidence": "Schema therapy is about as effective as CBT for treating depression[86]."
    },
    {
      "head": 3,
      "tail": 17,
      "type": "has_outcome",
      "evidence": "In adolescent patients with depression, CBT is also a recommended option with plenty of evidence from multiple trials."
    },
    {
      "head": 3,
      "tail": 19,
      "type": "treats",
      "evidence": "CBT is also recommended for patients with resistant depression in combination with antidepressants[85]."
    },
    {
      "head": 31,
      "tail": 19,
      "type": "treats",
      "evidence": "CBT is also recommended for patients with resistant depression in combination with antidepressants[85]."
    },
    {
      "head": 2,
      "tail": 1,
      "type": "treats",
      "evidence": "Psychodynamic therapy’s efficacy in the acute phase of MDD is well-established compared to other forms of psycho- therapy."
    },
    {
      "head": 3,
      "tail": 1,
      "type": "treats",
      "evidence": "The application of group therapy (GT) to MDD remains limited."
    },
    {
      "head": 4,
      "tail": 6,
      "type": "treats",
      "evidence": "Group CBT for patients with subthreshold depression is an effective post-depressive- symptomatology treatment but not during the follow-up period[99]."
    },
    {
      "head": 5,
      "tail": 1,
      "type": "treats",
      "evidence": "Some data support the efficacy of specific types of GT inspired by CBT and IPT[96-98]."
    },
    {
      "head": 7,
      "tail": 1,
      "type": "treats",
      "evidence": "Supportive GT and group CBT reduce depressive symptoms[96], especially in patients with common comorbid conditions[100]."
    },
    {
      "head": 4,
      "tail": 1,
      "type": "treats",
      "evidence": "Supportive GT and group CBT reduce depressive symptoms[96], especially in patients with common comorbid conditions[100]."
    },
    {
      "head": 8,
      "tail": 1,
      "type": "treats",
      "evidence": "Studies have shown that eight weeks of MBCT treatment during remission reduces relapse."
    },
    {
      "head": 9,
      "tail": 1,
      "type": "treats",
      "evidence": "Thus, it is a potential alternative to reduce, or even stop, antidepressant treatment without increasing the risk of depressive recurrence, especially for patients at a high risk of relapse (i.e., patients with more than two previous episodes and patients who have experienced childhood abuse or trauma)[102]."
    },
    {
      "head": 10,
      "tail": 12,
      "type": "treats",
      "evidence": "Psycho-education: This type of intervention educates depressed patients and (with their permission) family members involved in the patient’s life about depression symptoms and management."
    },
    {
      "head": 11,
      "tail": 12,
      "type": "treats",
      "evidence": "Most guidelines for treating depression, including the National Institute for Health and Care Excellence, the American Psychiatric Association, and the Royal Australian and New Zealand College of Psychiatrists, recommend that depressed patients perform regular physical activity to alleviate symptoms and prevent relapses[104]."
    },
    {
      "head": 13,
      "tail": 12,
      "type": "treats",
      "evidence": "Although psychotherapy is effective for treating depression and improving patients’ quality of life, its direct actions against depressive symptoms are not fully understood [106]."
    },
    {
      "head": 14,
      "tail": 12,
      "type": "treats",
      "evidence": "Brief forms (six to eight sessions) of CBT and PST have already shown their effectiveness for treating depression[108]."
    },
    {
      "head": 15,
      "tail": 12,
      "type": "treats",
      "evidence": "Brief forms (six to eight sessions) of CBT and PST have already shown their effectiveness for treating depression[108]."
    },
    {
      "head": 16,
      "tail": 17,
      "type": "treats",
      "evidence": "ECT is the most well-known treatment for resistant depression, and solid evidence supports its effectiveness and safety."
    },
    {
      "head": 16,
      "tail": 19,
      "type": "treats",
      "evidence": "ECT reduces the number of hospital readmissions and lightens the burden of depression, leading to a better quality of life[111,112]."
    },
    {
      "head": 16,
      "tail": 12,
      "type": "treats",
      "evidence": "Nevertheless, some people still consider ECT as the last option for treating depression, even though most studies indicate that ECT is more beneficial in patients with fewer pharmacological treatments[114-116]."
    },
    {
      "head": 20,
      "tail": 12,
      "type": "treats",
      "evidence": "Recent literature shows a significant difference between rTMS and fictitious stimulation regarding its improvements in depressive symptoms[127]."
    },
    {
      "head": 21,
      "tail": 12,
      "type": "treats",
      "evidence": "It can be used as a complementary intervention or as monotherapy to reduce depressive symptoms in unipolar or bipolar depression patients[135]."
    },
    {
      "head": 8,
      "tail": 33,
      "type": "has_outcome",
      "evidence": "Studies have shown that eight weeks of MBCT treatment during remission reduces relapse."
    },
    {
      "head": 8,
      "tail": 32,
      "type": "has_outcome",
      "evidence": "Studies have shown that eight weeks of MBCT treatment during remission reduces relapse."
    },
    {
      "head": 2,
      "tail": 31,
      "type": "has_outcome",
      "evidence": "Psychodynamic therapy’s efficacy in the acute phase of MDD is well-established compared to other forms of psycho- therapy."
    },
    {
      "head": 16,
      "tail": 39,
      "type": "has_outcome",
      "evidence": "ECT is the most well-known treatment for resistant depression, and solid evidence supports its effectiveness and safety."
    },
    {
      "head": 16,
      "tail": 40,
      "type": "has_outcome",
      "evidence": "ECT is the most well-known treatment for resistant depression, and solid evidence supports its effectiveness and safety."
    },
    {
      "head": 16,
      "tail": 41,
      "type": "has_outcome",
      "evidence": "ECT reduces the number of hospital readmissions and lightens the burden of depression, leading to a better quality of life[111,112]."
    },
    {
      "head": 16,
      "tail": 38,
      "type": "has_outcome",
      "evidence": "ECT reduces the number of hospital readmissions and lightens the burden of depression, leading to a better quality of life[111,112]."
    },
    {
      "head": 16,
      "tail": 42,
      "type": "has_outcome",
      "evidence": "Advances in anesthesia and ECT techniques have decreased complications related to ECT while also improving cognitive outcomes and patient satisfaction."
    },
    {
      "head": 16,
      "tail": 43,
      "type": "has_outcome",
      "evidence": "Advances in anesthesia and ECT techniques have decreased complications related to ECT while also improving cognitive outcomes and patient satisfaction."
    },
    {
      "head": 16,
      "tail": 44,
      "type": "has_outcome",
      "evidence": "Advances in anesthesia and ECT techniques have decreased complications related to ECT while also improving cognitive outcomes and patient satisfaction."
    },
    {
      "head": 20,
      "tail": 45,
      "type": "has_outcome",
      "evidence": "Treatments combining rTMS and antidepressants are significantly more effective than placebo conditions, with mild side effects and good acceptability[129]."
    },
    {
      "head": 20,
      "tail": 46,
      "type": "has_outcome",
      "evidence": "Treatments combining rTMS and antidepressants are significantly more effective than placebo conditions, with mild side effects and good acceptability[129]."
    },
    {
      "head": 21,
      "tail": 47,
      "type": "has_outcome",
      "evidence": "The tDCS technique significantly outperforms the simulator in terms of the rate of response and remission[132]."
    },
    {
      "head": 21,
      "tail": 32,
      "type": "has_outcome",
      "evidence": "The tDCS technique significantly outperforms the simulator in terms of the rate of response and remission[132]."
    },
    {
      "head": 21,
      "tail": 48,
      "type": "has_outcome",
      "evidence": "The antidepressant effects of tDCS may involve long-term neuroplastic changes that continue to occur even after the acute phase of treatment, which explains its delayed efficacy[135]."
    },
    {
      "head": 10,
      "tail": 35,
      "type": "has_outcome",
      "evidence": "Many studies have highlighted the role of psycho-education in improving the clinical course, treatment adherence, and psychosocial functioning in patients with depression[103]."
    },
    {
      "head": 10,
      "tail": 36,
      "type": "has_outcome",
      "evidence": "Many studies have highlighted the role of psycho-education in improving the clinical course, treatment adherence, and psychosocial functioning in patients with depression[103]."
    },
    {
      "head": 10,
      "tail": 37,
      "type": "has_outcome",
      "evidence": "Many studies have highlighted the role of psycho-education in improving the clinical course, treatment adherence, and psychosocial functioning in patients with depression[103]."
    },
    {
      "head": 11,
      "tail": 38,
      "type": "has_outcome",
      "evidence": "Exercise also promotes improvements in one’s quality of life in general[105]."
    },
    {
      "head": 11,
      "tail": 30,
      "type": "has_outcome",
      "evidence": "Most guidelines for treating depression, including the National Institute for Health and Care Excellence, the American Psychiatric Association, and the Royal Australian and New Zealand College of Psychiatrists, recommend that depressed patients perform regular physical activity to alleviate symptoms and prevent relapses[104]."
    },
    {
      "head": 11,
      "tail": 33,
      "type": "has_outcome",
      "evidence": "Most guidelines for treating depression, including the National Institute for Health and Care Excellence, the American Psychiatric Association, and the Royal Australian and New Zealand College of Psychiatrists, recommend that depressed patients perform regular physical activity to alleviate symptoms and prevent relapses[104]."
    },
    {
      "head": 8,
      "tail": 49,
      "type": "reports",
      "evidence": "Studies have shown that eight weeks of MBCT treatment during remission reduces relapse."
    },
    {
      "head": 14,
      "tail": 50,
      "type": "reports",
      "evidence": "Brief forms (six to eight sessions) of CBT and PST have already shown their effectiveness for treating depression[108]."
    },
    {
      "head": 15,
      "tail": 50,
      "type": "reports",
      "evidence": "Brief forms (six to eight sessions) of CBT and PST have already shown their effectiveness for treating depression[108]."
    },
    {
      "head": 2,
      "tail": 1,
      "type": "treats",
      "evidence": "VNS VNS is a therapeutic method that has been used for the last sixteen years to treat resistant unilateral or bipolar depression."
    },
    {
      "head": 2,
      "tail": 3,
      "type": "treats",
      "evidence": "Since the turn of the century, numerous studies have demonstrated the efficacy of VNS in resistant depression"
    },
    {
      "head": 2,
      "tail": 4,
      "type": "reports",
      "evidence": "However, only one randomized, double-blind, controlled trial comparing VNS with usual medical treatment has been conducted over a short period of 10 wk"
    },
    {
      "head": 2,
      "tail": 5,
      "type": "reports",
      "evidence": "However, VNS has demonstrated progressively increasing improvements in depressive symptoms, with significant positive outcomes observed after six to 12 mo"
    },
    {
      "head": 2,
      "tail": 6,
      "type": "reports",
      "evidence": "However, VNS has demonstrated progressively increasing improvements in depressive symptoms, with significant positive outcomes observed after six to 12 mo; these benefits can last for up to two years"
    },
    {
      "head": 8,
      "tail": 7,
      "type": "treats",
      "evidence": "According to the literature, DBS of the subgenual cingulate white matter (Brodmann area = BA 25) elicited a clinical response in 60% of resistant depression patients after six months and clinical remission in 35% of patients, with benefits maintained for over 12 mo"
    },
    {
      "head": 8,
      "tail": 9,
      "type": "reports",
      "evidence": "According to the literature, DBS of the subgenual cingulate white matter (Brodmann area = BA 25) elicited a clinical response in 60% of resistant depression patients after six months and clinical remission in 35% of patients, with benefits maintained for over 12 mo"
    },
    {
      "head": 8,
      "tail": 10,
      "type": "reports",
      "evidence": "According to the literature, DBS of the subgenual cingulate white matter (Brodmann area = BA 25) elicited a clinical response in 60% of resistant depression patients after six months and clinical remission in 35% of patients, with benefits maintained for over 12 mo"
    },
    {
      "head": 8,
      "tail": 11,
      "type": "reports",
      "evidence": "According to the literature, DBS of the subgenual cingulate white matter (Brodmann area = BA 25) elicited a clinical response in 60% of resistant depression patients after six months and clinical remission in 35% of patients, with benefits maintained for over 12 mo"
    },
    {
      "head": 8,
      "tail": 12,
      "type": "reports",
      "evidence": "According to the literature, DBS of the subgenual cingulate white matter (Brodmann area = BA 25) elicited a clinical response in 60% of resistant depression patients after six months and clinical remission in 35% of patients, with benefits maintained for over 12 mo"
    },
    {
      "head": 8,
      "tail": 13,
      "type": "treats",
      "evidence": "The stimulation of other targets, in particular the nucleus accumbens, to treat resistant depression has gained interest recently."
    },
    {
      "head": 15,
      "tail": 17,
      "type": "treats",
      "evidence": "This technique is still being investigated as a viable alternative to ECT to treat many psychiatric disorders."
    },
    {
      "head": 15,
      "tail": 18,
      "type": "has_outcome",
      "evidence": "Evidence supporting its effectiveness on depressive symptoms continues to grow, and it appears to induce fewer neurocognitive effects than ECT"
    },
    {
      "head": 19,
      "tail": 20,
      "type": "has_outcome",
      "evidence": "The first description of reduced depression symptoms due to intense light exposure was presented in 1984"
    },
    {
      "head": 19,
      "tail": 21,
      "type": "reports",
      "evidence": "Optimal improvements were obtained with bright light exposure of 2500 Lux for two hours per day, with morning exposure shown to be superior to evening exposure"
    },
    {
      "head": 19,
      "tail": 22,
      "type": "reports",
      "evidence": "Optimal improvements were obtained with bright light exposure of 2500 Lux for two hours per day, with morning exposure shown to be superior to evening exposure"
    },
    {
      "head": 19,
      "tail": 23,
      "type": "reports",
      "evidence": "A review and meta-analysis showed that more intense (but shorter) exposures (10000 Lux for half an hour per day or 6000 Lux for 1.5 h per day) have the same efficacy."
    },
    {
      "head": 19,
      "tail": 24,
      "type": "reports",
      "evidence": "A review and meta-analysis showed that more intense (but shorter) exposures (10000 Lux for half an hour per day or 6000 Lux for 1.5 h per day) have the same efficacy."
    },
    {
      "head": 19,
      "tail": 25,
      "type": "reports",
      "evidence": "A review and meta-analysis showed that more intense (but shorter) exposures (10000 Lux for half an hour per day or 6000 Lux for 1.5 h per day) have the same efficacy."
    },
    {
      "head": 19,
      "tail": 26,
      "type": "reports",
      "evidence": "A review and meta-analysis showed that more intense (but shorter) exposures (10000 Lux for half an hour per day or 6000 Lux for 1.5 h per day) have the same efficacy."
    },
    {
      "head": 19,
      "tail": 27,
      "type": "treats",
      "evidence": "Importantly, this treatment method is effective both for those with seasonal and non-seasonal depression."
    },
    {
      "head": 29,
      "tail": 28,
      "type": "treats",
      "evidence": "ECT remains the most documented and effective method in this category for patients with depression."
    },
    {
      "head": 33,
      "tail": 36,
      "type": "treats",
      "evidence": "The three principal methods available to caregivers are antidepressants, specifically structured psychotherapies, and somatic approaches."
    },
    {
      "head": 34,
      "tail": 36,
      "type": "treats",
      "evidence": "The three principal methods available to caregivers are antidepressants, specifically structured psychotherapies, and somatic approaches."
    },
    {
      "head": 35,
      "tail": 36,
      "type": "treats",
      "evidence": "The three principal methods available to caregivers are antidepressants, specifically structured psychotherapies, and somatic approaches."
    },
    {
      "head": 37,
      "tail": 38,
      "type": "treats",
      "evidence": "ECT is the only somatic treatment with confirmed indications for certain forms of depression."
    },
    {
      "head": 3,
      "tail": 1,
      "type": "treats",
      "evidence": "Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial."
    },
    {
      "head": 4,
      "tail": 1,
      "type": "treats",
      "evidence": "Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial."
    },
    {
      "head": 5,
      "tail": 1,
      "type": "treats",
      "evidence": "Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial."
    },
    {
      "head": 2,
      "tail": 1,
      "type": "affects",
      "evidence": "Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial."
    },
    {
      "head": 6,
      "tail": 3,
      "type": "compares",
      "evidence": "Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial."
    },
    {
      "head": 6,
      "tail": 4,
      "type": "compares",
      "evidence": "Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial."
    },
    {
      "head": 6,
      "tail": 5,
      "type": "compares",
      "evidence": "Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial."
    },
    {
      "head": 8,
      "tail": 7,
      "type": "treats",
      "evidence": "Phenelzine treatment of melancholia."
    },
    {
      "head": 13,
      "tail": 12,
      "type": "treats",
      "evidence": "A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression."
    },
    {
      "head": 14,
      "tail": 12,
      "type": "treats",
      "evidence": "A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression."
    },
    {
      "head": 16,
      "tail": 19,
      "type": "treats",
      "evidence": "Tranylcypromine vs venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report."
    },
    {
      "head": 17,
      "tail": 19,
      "type": "treats",
      "evidence": "Tranylcypromine vs venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report."
    },
    {
      "head": 18,
      "tail": 19,
      "type": "treats",
      "evidence": "Tranylcypromine vs venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report."
    },
    {
      "head": 20,
      "tail": 16,
      "type": "compares",
      "evidence": "Tranylcypromine vs venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report."
    },
    {
      "head": 20,
      "tail": 17,
      "type": "compares",
      "evidence": "Tranylcypromine vs venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report."
    },
    {
      "head": 20,
      "tail": 18,
      "type": "compares",
      "evidence": "Tranylcypromine vs venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report."
    },
    {
      "head": 24,
      "tail": 23,
      "type": "treats",
      "evidence": "Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications."
    },
    {
      "head": 26,
      "tail": 25,
      "type": "treats",
      "evidence": "Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis."
    },
    {
      "head": 27,
      "tail": 25,
      "type": "treats",
      "evidence": "Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis."
    },
    {
      "head": 29,
      "tail": 26,
      "type": "compares",
      "evidence": "Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis."
    },
    {
      "head": 29,
      "tail": 27,
      "type": "compares",
      "evidence": "Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis."
    },
    {
      "head": 30,
      "tail": 34,
      "type": "treats",
      "evidence": "Amitriptyline for inpatients and SSRIs for outpatients with depression?"
    },
    {
      "head": 32,
      "tail": 34,
      "type": "treats",
      "evidence": "Amitriptyline for inpatients and SSRIs for outpatients with depression?"
    },
    {
      "head": 35,
      "tail": 34,
      "type": "treats",
      "evidence": "SSRIS vs tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability."
    },
    {
      "head": 36,
      "tail": 34,
      "type": "treats",
      "evidence": "SSRIS vs tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability."
    },
    {
      "head": 38,
      "tail": 35,
      "type": "compares",
      "evidence": "SSRIS vs tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability."
    },
    {
      "head": 38,
      "tail": 36,
      "type": "compares",
      "evidence": "SSRIS vs tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability."
    },
    {
      "head": 35,
      "tail": 39,
      "type": "has_outcome",
      "evidence": "SSRIS vs tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability."
    },
    {
      "head": 35,
      "tail": 40,
      "type": "has_outcome",
      "evidence": "SSRIS vs tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability."
    },
    {
      "head": 36,
      "tail": 39,
      "type": "has_outcome",
      "evidence": "SSRIS vs tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability."
    },
    {
      "head": 36,
      "tail": 40,
      "type": "has_outcome",
      "evidence": "SSRIS vs tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability."
    },
    {
      "head": 42,
      "tail": 41,
      "type": "reports",
      "evidence": "Which depressions respond to placebo?"
    },
    {
      "head": 44,
      "tail": 43,
      "type": "treats",
      "evidence": "The endogenous--neurotic distinction as a predictor of response to antidepressant drugs."
    },
    {
      "head": 45,
      "tail": 46,
      "type": "treats",
      "evidence": "Depressive typologies and response to amitriptyline."
    },
    {
      "head": 48,
      "tail": 47,
      "type": "treats",
      "evidence": "Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines."
    },
    {
      "head": 50,
      "tail": 52,
      "type": "has_outcome",
      "evidence": "The efficacy of fluoxetine as an antidepressant in the short and long term."
    },
    {
      "head": 50,
      "tail": 53,
      "type": "has_outcome",
      "evidence": "The efficacy of fluoxetine as an antidepressant in the short and long term."
    },
    {
      "head": 55,
      "tail": 57,
      "type": "treats",
      "evidence": "Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis."
    },
    {
      "head": 56,
      "tail": 57,
      "type": "treats",
      "evidence": "Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis."
    },
    {
      "head": 58,
      "tail": 55,
      "type": "compares",
      "evidence": "Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis."
    },
    {
      "head": 58,
      "tail": 56,
      "type": "compares",
      "evidence": "Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis."
    },
    {
      "head": 59,
      "tail": 60,
      "type": "treats",
      "evidence": "Fluoxetine vs other types of pharmacotherapy for depression."
    },
    {
      "head": 61,
      "tail": 60,
      "type": "treats",
      "evidence": "Fluoxetine vs other types of pharmacotherapy for depression."
    },
    {
      "head": 62,
      "tail": 59,
      "type": "compares",
      "evidence": "Fluoxetine vs other types of pharmacotherapy for depression."
    },
    {
      "head": 62,
      "tail": 61,
      "type": "compares",
      "evidence": "Fluoxetine vs other types of pharmacotherapy for depression."
    },
    {
      "head": 63,
      "tail": 65,
      "type": "treats",
      "evidence": "A meta-analysis of the efficacy and tolerability of paroxetine vs tricyclic antidepressants in the treatment of major depression."
    },
    {
      "head": 64,
      "tail": 65,
      "type": "treats",
      "evidence": "A meta-analysis of the efficacy and tolerability of paroxetine vs tricyclic antidepressants in the treatment of major depression."
    },
    {
      "head": 66,
      "tail": 63,
      "type": "compares",
      "evidence": "A meta-analysis of the efficacy and tolerability of paroxetine vs tricyclic antidepressants in the treatment of major depression."
    },
    {
      "head": 66,
      "tail": 64,
      "type": "compares",
      "evidence": "A meta-analysis of the efficacy and tolerability of paroxetine vs tricyclic antidepressants in the treatment of major depression."
    },
    {
      "head": 63,
      "tail": 67,
      "type": "has_outcome",
      "evidence": "A meta-analysis of the efficacy and tolerability of paroxetine vs tricyclic antidepressants in the treatment of major depression."
    },
    {
      "head": 63,
      "tail": 68,
      "type": "has_outcome",
      "evidence": "A meta-analysis of the efficacy and tolerability of paroxetine vs tricyclic antidepressants in the treatment of major depression."
    },
    {
      "head": 64,
      "tail": 67,
      "type": "has_outcome",
      "evidence": "A meta-analysis of the efficacy and tolerability of paroxetine vs tricyclic antidepressants in the treatment of major depression."
    },
    {
      "head": 64,
      "tail": 68,
      "type": "has_outcome",
      "evidence": "A meta-analysis of the efficacy and tolerability of paroxetine vs tricyclic antidepressants in the treatment of major depression."
    },
    {
      "head": 70,
      "tail": 71,
      "type": "treats",
      "evidence": "Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis."
    },
    {
      "head": 72,
      "tail": 71,
      "type": "treats",
      "evidence": "Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis."
    },
    {
      "head": 73,
      "tail": 71,
      "type": "treats",
      "evidence": "Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis."
    },
    {
      "head": 74,
      "tail": 70,
      "type": "compares",
      "evidence": "Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis."
    },
    {
      "head": 74,
      "tail": 72,
      "type": "compares",
      "evidence": "Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis."
    },
    {
      "head": 74,
      "tail": 73,
      "type": "compares",
      "evidence": "Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis."
    },
    {
      "head": 75,
      "tail": 76,
      "type": "treats",
      "evidence": "Escitalopram: a review of its use in the management of major depressive disorder in adults."
    },
    {
      "head": 78,
      "tail": 80,
      "type": "has_outcome",
      "evidence": "Comprehensive analysis of remission (COMPARE) with venlafaxine vs SSRIs."
    },
    {
      "head": 79,
      "tail": 80,
      "type": "has_outcome",
      "evidence": "Comprehensive analysis of remission (COMPARE) with venlafaxine vs SSRIs."
    },
    {
      "head": 83,
      "tail": 82,
      "type": "has_outcome",
      "evidence": "Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major"
    },
    {
      "head": 84,
      "tail": 82,
      "type": "has_outcome",
      "evidence": "Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major"
    },
    {
      "head": 2,
      "tail": 5,
      "type": "treats",
      "evidence": "The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression"
    },
    {
      "head": 3,
      "tail": 5,
      "type": "treats",
      "evidence": "The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression"
    },
    {
      "head": 4,
      "tail": 5,
      "type": "treats",
      "evidence": "The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression"
    },
    {
      "head": 6,
      "tail": 2,
      "type": "compares",
      "evidence": "The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta- analysis"
    },
    {
      "head": 6,
      "tail": 3,
      "type": "compares",
      "evidence": "The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta- analysis"
    },
    {
      "head": 6,
      "tail": 4,
      "type": "compares",
      "evidence": "The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta- analysis"
    },
    {
      "head": 8,
      "tail": 7,
      "type": "treats",
      "evidence": "Comparative efficacy and acceptability of 12 new- generation antidepressants: a multiple-treatments meta-analysis"
    },
    {
      "head": 9,
      "tail": 8,
      "type": "compares",
      "evidence": "Comparative efficacy and acceptability of 12 new- generation antidepressants: a multiple-treatments meta-analysis"
    },
    {
      "head": 10,
      "tail": 5,
      "type": "treats",
      "evidence": "Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram vs reboxetine)"
    },
    {
      "head": 11,
      "tail": 5,
      "type": "treats",
      "evidence": "Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram vs reboxetine)"
    },
    {
      "head": 12,
      "tail": 10,
      "type": "compares",
      "evidence": "Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram vs reboxetine)"
    },
    {
      "head": 12,
      "tail": 11,
      "type": "compares",
      "evidence": "Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram vs reboxetine)"
    },
    {
      "head": 17,
      "tail": 20,
      "type": "treats",
      "evidence": "A comparison of venlafaxine, trazodone, and placebo in major depression"
    },
    {
      "head": 18,
      "tail": 20,
      "type": "treats",
      "evidence": "A comparison of venlafaxine, trazodone, and placebo in major depression"
    },
    {
      "head": 19,
      "tail": 20,
      "type": "treats",
      "evidence": "A comparison of venlafaxine, trazodone, and placebo in major depression"
    },
    {
      "head": 21,
      "tail": 24,
      "type": "treats",
      "evidence": "A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder"
    },
    {
      "head": 22,
      "tail": 24,
      "type": "treats",
      "evidence": "A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder"
    },
    {
      "head": 23,
      "tail": 24,
      "type": "treats",
      "evidence": "A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder"
    },
    {
      "head": 26,
      "tail": 27,
      "type": "treats",
      "evidence": "Vortioxetine: a novel antidepressant for the treatment of major depressive disorder"
    },
    {
      "head": 28,
      "tail": 30,
      "type": "treats",
      "evidence": "Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression)"
    },
    {
      "head": 29,
      "tail": 30,
      "type": "treats",
      "evidence": "Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression)"
    },
    {
      "head": 32,
      "tail": 34,
      "type": "treats",
      "evidence": "A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder"
    },
    {
      "head": 33,
      "tail": 34,
      "type": "treats",
      "evidence": "A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder"
    },
    {
      "head": 38,
      "tail": 39,
      "type": "reports",
      "evidence": "Trazodone: a 5-year review of antidepressant efficacy"
    },
    {
      "head": 40,
      "tail": 41,
      "type": "treats",
      "evidence": "Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine"
    },
    {
      "head": 42,
      "tail": 43,
      "type": "treats",
      "evidence": "Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder"
    },
    {
      "head": 44,
      "tail": 45,
      "type": "treats",
      "evidence": "Ketamine for treatment-resistant depression: recent developments and clinical applications"
    },
    {
      "head": 46,
      "tail": 47,
      "type": "treats",
      "evidence": "New use for an old drug: oral ketamine for treatment-resistant depression"
    },
    {
      "head": 48,
      "tail": 45,
      "type": "treats",
      "evidence": "Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant"
    },
    {
      "head": 50,
      "tail": 53,
      "type": "treats",
      "evidence": "A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders"
    },
    {
      "head": 2,
      "tail": 1,
      "type": "treats",
      "evidence": "Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder."
    },
    {
      "head": 2,
      "tail": 3,
      "type": "treats",
      "evidence": "Intranasal esketamine: A novel drug for treatment-resistant depression."
    },
    {
      "head": 2,
      "tail": 23,
      "type": "has_outcome",
      "evidence": "Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder."
    },
    {
      "head": 2,
      "tail": 24,
      "type": "has_outcome",
      "evidence": "Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder."
    },
    {
      "head": 5,
      "tail": 4,
      "type": "treats",
      "evidence": "Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression."
    },
    {
      "head": 6,
      "tail": 4,
      "type": "treats",
      "evidence": "Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression."
    },
    {
      "head": 7,
      "tail": 8,
      "type": "treats",
      "evidence": "Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial."
    },
    {
      "head": 9,
      "tail": 7,
      "type": "compares",
      "evidence": "Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial."
    },
    {
      "head": 10,
      "tail": 4,
      "type": "treats",
      "evidence": "Molecular and Cellular Mechanisms of Rapid- Acting Antidepressants Ketamine and Scopolamine."
    },
    {
      "head": 12,
      "tail": 11,
      "type": "treats",
      "evidence": "Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder"
    },
    {
      "head": 13,
      "tail": 11,
      "type": "treats",
      "evidence": "Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder"
    },
    {
      "head": 14,
      "tail": 15,
      "type": "treats",
      "evidence": "Clinical relevance of findings in trials of CBT for depression."
    },
    {
      "head": 16,
      "tail": 15,
      "type": "treats",
      "evidence": "Psychotherapy for depression: a randomized clinical trial comparing schema therapy and cognitive behavior therapy."
    },
    {
      "head": 17,
      "tail": 15,
      "type": "treats",
      "evidence": "Psychotherapy for depression: a randomized clinical trial comparing schema therapy and cognitive behavior therapy."
    },
    {
      "head": 18,
      "tail": 15,
      "type": "treats",
      "evidence": "Psychotherapy for depression: a randomized clinical trial comparing schema therapy and cognitive behavior therapy."
    },
    {
      "head": 20,
      "tail": 19,
      "type": "treats",
      "evidence": "Evidence Base Update of Psychosocial Treatments for Child and Adolescent Depression."
    },
    {
      "head": 20,
      "tail": 21,
      "type": "treats",
      "evidence": "Psychological Treatment of Depression in People Aged 65 Years and Over"
    },
    {
      "head": 22,
      "tail": 21,
      "type": "treats",
      "evidence": "Clinician’s Quick Guide to Interpersonal Psychotherapy."
    },
    {
      "head": 26,
      "tail": 25,
      "type": "affects",
      "evidence": "CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls."
    },
    {
      "head": 28,
      "tail": 29,
      "type": "has_outcome",
      "evidence": "Psychological Treatment of Depression in People Aged 65 Years and Over: A Systematic Review of Efficacy, Safety, and Cost-Effectiveness."
    },
    {
      "head": 2,
      "tail": 1,
      "type": "treats",
      "evidence": "Effectiveness of problem-solving therapy for older, primary care patients with depression"
    },
    {
      "head": 6,
      "tail": 4,
      "type": "treats",
      "evidence": "Problem-solving therapy vs supportive therapy in geriatric major depression with executive dysfunction"
    },
    {
      "head": 11,
      "tail": 9,
      "type": "treats",
      "evidence": "Psychotherapy for Major Depressive Disorder and Generalized Anxiety Disorder"
    },
    {
      "head": 11,
      "tail": 10,
      "type": "treats",
      "evidence": "Psychotherapy for Major Depressive Disorder and Generalized Anxiety Disorder"
    },
    {
      "head": 13,
      "tail": 12,
      "type": "treats",
      "evidence": "Developmentalist metatheory of depression and psychotherapy"
    },
    {
      "head": 15,
      "tail": 17,
      "type": "treats",
      "evidence": "Professional and paraprofessional group treatments for depression"
    },
    {
      "head": 16,
      "tail": 17,
      "type": "treats",
      "evidence": "Professional and paraprofessional group treatments for depression: a comparison of cognitive-behavioral and mutual support interventions"
    },
    {
      "head": 18,
      "tail": 19,
      "type": "treats",
      "evidence": "Interpersonal psychotherapy adapted for the group setting in the treatment of postpartum depression"
    },
    {
      "head": 20,
      "tail": 21,
      "type": "treats",
      "evidence": "Group interpersonal psychotherapy for depression in rural Uganda"
    },
    {
      "head": 23,
      "tail": 24,
      "type": "treats",
      "evidence": "Systematic review and meta-analysis of group cognitive behavioural psychotherapy treatment for sub-clinical depression"
    },
    {
      "head": 27,
      "tail": 28,
      "type": "treats",
      "evidence": "Mindfulness-based cognitive therapy for patients with chronic, treatment-resistant depression"
    },
    {
      "head": 31,
      "tail": 30,
      "type": "treats",
      "evidence": "Effectiveness of psychoeducation for depression"
    },
    {
      "head": 33,
      "tail": 34,
      "type": "treats",
      "evidence": "Portuguese and Brazilian guidelines for the treatment of depression: exercise as medicine"
    },
    {
      "head": 36,
      "tail": 35,
      "type": "treats",
      "evidence": "Exercise and severe major depression: effect on symptom severity and quality of life at discharge in an inpatient cohort"
    },
    {
      "head": 37,
      "tail": 38,
      "type": "treats",
      "evidence": "Effect of psychotherapy for depression on quality of life"
    },
    {
      "head": 40,
      "tail": 41,
      "type": "treats",
      "evidence": "Patient Extratherapeutic Interpersonal Problems and Response to Psychotherapy for Depression"
    },
    {
      "head": 42,
      "tail": 43,
      "type": "treats",
      "evidence": "Brief psychotherapy for depression"
    },
    {
      "head": 44,
      "tail": 45,
      "type": "treats",
      "evidence": "Efficacy and safety of electroconvulsive therapy in depressive disorders"
    },
    {
      "head": 46,
      "tail": 47,
      "type": "has_outcome",
      "evidence": "Association of Electroconvulsive Therapy With Psychiatric Readmissions in US Hospitals"
    },
    {
      "head": 48,
      "tail": 49,
      "type": "has_outcome",
      "evidence": "Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy"
    },
    {
      "head": 50,
      "tail": 51,
      "type": "has_outcome",
      "evidence": "The mortality rate of electroconvulsive therapy"
    },
    {
      "head": 52,
      "tail": 53,
      "type": "has_outcome",
      "evidence": "In-hospital mortality among electroconvulsive therapy recipients"
    },
    {
      "head": 54,
      "tail": 55,
      "type": "has_outcome",
      "evidence": "Medication resistance and clinical response to electroconvulsive therapy"
    },
    {
      "head": 56,
      "tail": 58,
      "type": "has_outcome",
      "evidence": "Electroconvulsive Therapy and Risk of Dementia"
    },
    {
      "head": 59,
      "tail": 60,
      "type": "has_outcome",
      "evidence": "ECT in pregnancy"
    },
    {
      "head": 61,
      "tail": 62,
      "type": "has_outcome",
      "evidence": "The role of ECT in suicide prevention"
    },
    {
      "head": 63,
      "tail": 64,
      "type": "treats",
      "evidence": "Electroconvulsive therapy in movement disorders"
    },
    {
      "head": 65,
      "tail": 66,
      "type": "has_outcome",
      "evidence": "The use of electroconvulsive therapy in pregnancy"
    },
    {
      "head": 67,
      "tail": 68,
      "type": "has_outcome",
      "evidence": "Improvement after two sessions of electroconvulsive therapy predicts final remission in in-patients with major depression"
    },
    {
      "head": 3,
      "tail": 1,
      "type": "affects",
      "evidence": "Effectiveness of problem-solving therapy for older, primary care patients with depression"
    },
    {
      "head": 22,
      "tail": 20,
      "type": "compares",
      "evidence": "Group interpersonal psychotherapy for depression in rural Uganda: a randomized controlled trial"
    },
    {
      "head": 2,
      "tail": 1,
      "type": "treats",
      "evidence": "Evidence for increased genetic risk load for major depression in patients assigned to electroconvulsive therapy."
    },
    {
      "head": 2,
      "tail": 21,
      "type": "has_outcome",
      "evidence": "Volume increase in the dentate gyrus after electroconvulsive therapy in depressed patients as measured with 7T."
    },
    {
      "head": 3,
      "tail": 21,
      "type": "has_outcome",
      "evidence": "Volume increase in the dentate gyrus after electroconvulsive therapy in depressed patients as measured with 7T."
    },
    {
      "head": 2,
      "tail": 22,
      "type": "has_outcome",
      "evidence": "Shared preventive factors associated with relapse after a response to electroconvulsive therapy in four major psychiatric disorders."
    },
    {
      "head": 2,
      "tail": 6,
      "type": "treats",
      "evidence": "Effects of Electroconvulsive Therapy on Depression and Its Potential Mechanism."
    },
    {
      "head": 7,
      "tail": 6,
      "type": "treats",
      "evidence": "Recovering from depression with repetitive transcranial magnetic stimulation (rTMS): a systematic review and meta-analysis of preclinical studies."
    },
    {
      "head": 9,
      "tail": 8,
      "type": "treats",
      "evidence": "Augmenting pharmacotherapy with neuromodulation techniques for the treatment of bipolar disorder: a focus on the effects of mood stabilizers on cortical excitability."
    },
    {
      "head": 9,
      "tail": 25,
      "type": "has_outcome",
      "evidence": "Augmenting pharmacotherapy with neuromodulation techniques for the treatment of bipolar disorder: a focus on the effects of mood stabilizers on cortical excitability."
    },
    {
      "head": 10,
      "tail": 11,
      "type": "treats",
      "evidence": "Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review."
    },
    {
      "head": 13,
      "tail": 12,
      "type": "treats",
      "evidence": "Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis."
    },
    {
      "head": 14,
      "tail": 15,
      "type": "treats",
      "evidence": "Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: An individual patient data meta-analysis."
    },
    {
      "head": 16,
      "tail": 6,
      "type": "treats",
      "evidence": "Pilot trial of home-administered transcranial direct current stimulation for the treatment of depression."
    },
    {
      "head": 17,
      "tail": 18,
      "type": "treats",
      "evidence": "Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects."
    },
    {
      "head": 17,
      "tail": 26,
      "type": "has_outcome",
      "evidence": "Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects."
    },
    {
      "head": 17,
      "tail": 19,
      "type": "treats",
      "evidence": "Effectiveness and safety of vagus nerve stimulation for severe treatment-resistant major depression in clinical practice after FDA approval: outcomes at 1 year."
    },
    {
      "head": 17,
      "tail": 27,
      "type": "has_outcome",
      "evidence": "Effectiveness and safety of vagus nerve stimulation for severe treatment-resistant major depression in clinical practice after FDA approval: outcomes at 1 year."
    },
    {
      "head": 20,
      "tail": 18,
      "type": "treats",
      "evidence": "Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine."
    },
    {
      "head": 21,
      "tail": 28,
      "type": "measured_by",
      "evidence": "Volume increase in the dentate gyrus after electroconvulsive therapy in depressed patients as measured with 7T."
    },
    {
      "head": 10,
      "tail": 23,
      "type": "has_outcome",
      "evidence": "Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review."
    },
    {
      "head": 10,
      "tail": 24,
      "type": "has_outcome",
      "evidence": "Meta-analysis of the Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression."
    },
    {
      "head": 7,
      "tail": 23,
      "type": "has_outcome",
      "evidence": "Meta-analysis of the Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression."
    },
    {
      "head": 7,
      "tail": 24,
      "type": "has_outcome",
      "evidence": "Meta-analysis of the Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression."
    },
    {
      "head": 14,
      "tail": 23,
      "type": "has_outcome",
      "evidence": "Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: An individual patient data meta-analysis."
    },
    {
      "head": 14,
      "tail": 24,
      "type": "has_outcome",
      "evidence": "Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: An individual patient data meta-analysis."
    },
    {
      "head": 33,
      "tail": 10,
      "type": "compares",
      "evidence": "Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review."
    },
    {
      "head": 30,
      "tail": 13,
      "type": "compares",
      "evidence": "Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis."
    },
    {
      "head": 34,
      "tail": 17,
      "type": "compares",
      "evidence": "Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects."
    },
    {
      "head": 17,
      "tail": 35,
      "type": "has_dosage",
      "evidence": "Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects."
    },
    {
      "head": 2,
      "tail": 1,
      "type": "treats",
      "evidence": "Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial"
    },
    {
      "head": 2,
      "tail": 4,
      "type": "treats",
      "evidence": "Vagus nerve stimulation for depression: efficacy and safety in a European study"
    },
    {
      "head": 6,
      "tail": 7,
      "type": "treats",
      "evidence": "Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression"
    },
    {
      "head": 8,
      "tail": 9,
      "type": "treats",
      "evidence": "Deep brain stimulation for treatment-resistant depression"
    },
    {
      "head": 11,
      "tail": 10,
      "type": "treats",
      "evidence": "Magnetic seizure therapy improves mood in refractory major depression"
    },
    {
      "head": 13,
      "tail": 14,
      "type": "treats",
      "evidence": "Magnetic Seizure Therapy: Towards Personalized Seizure Therapy for Major Depression"
    },
    {
      "head": 17,
      "tail": 16,
      "type": "treats",
      "evidence": "Morning vs evening light treatment for winter depression"
    },
    {
      "head": 19,
      "tail": 18,
      "type": "treats",
      "evidence": "The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence"
    },
    {
      "head": 3,
      "tail": 2,
      "type": "compares",
      "evidence": "Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial"
    },
    {
      "head": 11,
      "tail": 1,
      "type": "treats",
      "evidence": "Anxious depression is associated with poorer acute outcomes than nonanxious depression following antidepressant treatment."
    },
    {
      "head": 11,
      "tail": 3,
      "type": "treats",
      "evidence": "Anxious depression is associated with poorer acute outcomes than nonanxious depression following antidepressant treatment."
    },
    {
      "head": 11,
      "tail": 4,
      "type": "treats",
      "evidence": "Anxious depression is associated with poorer acute outcomes than nonanxious depression following antidepressant treatment."
    },
    {
      "head": 3,
      "tail": 14,
      "type": "has_outcome",
      "evidence": "Remission was significantly less likely and took longer to occur in these patients than in those with nonanxious depression."
    },
    {
      "head": 3,
      "tail": 16,
      "type": "has_outcome",
      "evidence": "Ratings of side effect frequency, intensity, and burden, as well as the number of serious adverse events, were significantly greater in the anxious depression group."
    },
    {
      "head": 3,
      "tail": 17,
      "type": "has_outcome",
      "evidence": "Ratings of side effect frequency, intensity, and burden, as well as the number of serious adverse events, were significantly greater in the anxious depression group."
    },
    {
      "head": 3,
      "tail": 18,
      "type": "has_outcome",
      "evidence": "Anxious depression is associated with poorer acute outcomes than nonanxious depression following antidepressant treatment."
    },
    {
      "head": 19,
      "tail": 3,
      "type": "affects",
      "evidence": "Remission was significantly less likely and took longer to occur in these patients than in those with nonanxious depression."
    },
    {
      "head": 19,
      "tail": 16,
      "type": "affects",
      "evidence": "Ratings of side effect frequency, intensity, and burden, as well as the number of serious adverse events, were significantly greater in the anxious depression group."
    },
    {
      "head": 19,
      "tail": 17,
      "type": "affects",
      "evidence": "Ratings of side effect frequency, intensity, and burden, as well as the number of serious adverse events, were significantly greater in the anxious depression group."
    },
    {
      "head": 20,
      "tail": 5,
      "type": "compares",
      "evidence": "A total of 2,876 adult outpatients with major depressive disorder, enrolled from 18 primary and 23 psychiatric care sites, received citalopram in Level 1 of STAR*D. In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286)."
    },
    {
      "head": 20,
      "tail": 6,
      "type": "compares",
      "evidence": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286)."
    },
    {
      "head": 20,
      "tail": 7,
      "type": "compares",
      "evidence": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286)."
    },
    {
      "head": 20,
      "tail": 8,
      "type": "compares",
      "evidence": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286)."
    },
    {
      "head": 20,
      "tail": 9,
      "type": "compares",
      "evidence": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286)."
    },
    {
      "head": 20,
      "tail": 10,
      "type": "compares",
      "evidence": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286)."
    },
    {
      "head": 5,
      "tail": 22,
      "type": "reports",
      "evidence": "A total of 2,876 adult outpatients with major depressive disorder, en- rolled from 18 primary and 23 psychiatric care sites, received citalopram in Level 1 of STAR*D."
    },
    {
      "head": 6,
      "tail": 23,
      "type": "reports",
      "evidence": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286)."
    },
    {
      "head": 7,
      "tail": 24,
      "type": "reports",
      "evidence": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286)."
    },
    {
      "head": 8,
      "tail": 25,
      "type": "reports",
      "evidence": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286)."
    },
    {
      "head": 9,
      "tail": 26,
      "type": "reports",
      "evidence": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286)."
    },
    {
      "head": 10,
      "tail": 27,
      "type": "reports",
      "evidence": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286)."
    },
    {
      "head": 3,
      "tail": 28,
      "type": "reports",
      "evidence": "In Level 1 of STAR*D, 53.2% of patients had anxious depression."
    },
    {
      "head": 14,
      "tail": 28,
      "type": "reports",
      "evidence": "In Level 1 of STAR*D, 53.2% of patients had anxious depression."
    },
    {
      "head": 1,
      "tail": 29,
      "type": "reports",
      "evidence": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned..."
    },
    {
      "head": 21,
      "tail": 30,
      "type": "reports",
      "evidence": "Patients were designated as having anxious depression if their anxiety/somatization factor score from the 17-item Hamilton Depression Rating Scale (HAM-D) was 7 or higher at baseline."
    },
    {
      "head": 2,
      "tail": 1,
      "type": "treats",
      "evidence": "anxious depression was defined as major depressive disorder with high levels of anxiety symptoms"
    },
    {
      "head": 3,
      "tail": 10,
      "type": "has_outcome",
      "evidence": "and not have been treat- ment resistant in an adequate trial of an antidepressant during the current episode"
    },
    {
      "head": 4,
      "tail": 8,
      "type": "has_outcome",
      "evidence": "The aim of citalopram treatment in Level 1 was to achieve symptom remission"
    },
    {
      "head": 4,
      "tail": 9,
      "type": "has_outcome",
      "evidence": "Dose adjustments were guided by recommendations in a treatment manual (www.star-d.org) that allowed individualized starting doses and dose adjustments to minimize side effects"
    },
    {
      "head": 11,
      "tail": 9,
      "type": "has_outcome",
      "evidence": "Patients could discontinue citalo- pram before 12 weeks if intolerable side effects made a medication change necessary"
    },
    {
      "head": 4,
      "tail": 13,
      "type": "has_dosage",
      "evidence": "Citalopram was to begin at 20 mg/day and be raised to 40 mg/day by weeks 2–4 and to 60 mg/day (final dose) by weeks 4–6."
    },
    {
      "head": 4,
      "tail": 14,
      "type": "has_dosage",
      "evidence": "Citalopram was to begin at 20 mg/day and be raised to 40 mg/day by weeks 2–4 and to 60 mg/day (final dose) by weeks 4–6."
    },
    {
      "head": 4,
      "tail": 15,
      "type": "has_dosage",
      "evidence": "Citalopram was to begin at 20 mg/day and be raised to 40 mg/day by weeks 2–4 and to 60 mg/day (final dose) by weeks 4–6."
    },
    {
      "head": 8,
      "tail": 17,
      "type": "reports",
      "evidence": "which was defined as QIDS-C score ≤5"
    },
    {
      "head": 12,
      "tail": 16,
      "type": "reports",
      "evidence": "FIGURE 1. Distribution of HAM-D Anxiety/Somatization Factor Scores in Patients Treated With Citalopram in Level 1 of STAR*D (N=2,876)"
    },
    {
      "head": 8,
      "tail": 17,
      "type": "measured_by",
      "evidence": "which was defined as QIDS-C score ≤5"
    },
    {
      "head": 9,
      "tail": 18,
      "type": "reports",
      "evidence": "if significant symptoms (as indicated by a QIDS-C score ≥9) were present after 9 weeks at maximally tolerated doses"
    },
    {
      "head": 9,
      "tail": 19,
      "type": "reports",
      "evidence": "Patients could opt to move to the next treatment level if they had intolerable side effects or if their QIDS-C score was >5 after a trial of adequate dosage and du- ration"
    },
    {
      "head": 2,
      "tail": 20,
      "type": "reports",
      "evidence": "anxious depression was de- fined as major depressive disorder with high levels of anxiety symptoms, as reflected in a HAM-D anxiety/somatization factor score ≥7"
    },
    {
      "head": 5,
      "tail": 21,
      "type": "reports",
      "evidence": "score ≥14 (indicating moderate severity) on the 17-item HAM-D"
    },
    {
      "head": 3,
      "tail": 1,
      "type": "treats",
      "evidence": "Baseline clinical and demographic features, treatment features, and rates of side effects and serious adverse events were compared between patients with anxious and nonanxious depression."
    },
    {
      "head": 7,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "Baseline clinical and demographic features, treatment features, and rates of side effects and serious adverse events were compared between patients with anxious and nonanxious depression."
    },
    {
      "head": 8,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "Baseline clinical and demographic features, treatment features, and rates of side effects and serious adverse events were compared between patients with anxious and nonanxious depression."
    },
    {
      "head": 7,
      "tail": 5,
      "type": "has_outcome",
      "evidence": "Baseline clinical and demographic features, treatment features, and rates of side effects and serious adverse events were compared between patients with anxious and nonanxious depression."
    },
    {
      "head": 8,
      "tail": 5,
      "type": "has_outcome",
      "evidence": "Baseline clinical and demographic features, treatment features, and rates of side effects and serious adverse events were compared between patients with anxious and nonanxious depression."
    },
    {
      "head": 7,
      "tail": 6,
      "type": "has_outcome",
      "evidence": "Baseline clinical and demographic features, treatment features, and rates of side effects and serious adverse events were compared between patients with anxious and nonanxious depression."
    },
    {
      "head": 8,
      "tail": 6,
      "type": "has_outcome",
      "evidence": "Baseline clinical and demographic features, treatment features, and rates of side effects and serious adverse events were compared between patients with anxious and nonanxious depression."
    },
    {
      "head": 7,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "Logistic regression models were used to compare remission and response rates after adjustment for baseline severity of depression (as measured by the QIDS-SR) and regional center."
    },
    {
      "head": 8,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "Logistic regression models were used to compare remission and response rates after adjustment for baseline severity of depression (as measured by the QIDS-SR) and regional center."
    },
    {
      "head": 7,
      "tail": 5,
      "type": "has_outcome",
      "evidence": "Logistic regression models were used to compare remission and response rates after adjustment for baseline severity of depression (as measured by the QIDS-SR) and regional center."
    },
    {
      "head": 8,
      "tail": 5,
      "type": "has_outcome",
      "evidence": "Logistic regression models were used to compare remission and response rates after adjustment for baseline severity of depression (as measured by the QIDS-SR) and regional center."
    },
    {
      "head": 4,
      "tail": 10,
      "type": "measured_by",
      "evidence": "Remission was defined as an exit HAM-D score ≤7 or last ob-served QIDS-SR score ≤5."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "reports",
      "evidence": "Remission was defined as an exit HAM-D score ≤7 or last ob-served QIDS-SR score ≤5."
    },
    {
      "head": 4,
      "tail": 13,
      "type": "reports",
      "evidence": "Remission was defined as an exit HAM-D score ≤7 or last ob-served QIDS-SR score ≤5."
    },
    {
      "head": 5,
      "tail": 11,
      "type": "measured_by",
      "evidence": "Response was defined as a reduction of ≥50% from baseline in the QIDS-SR score at the last assessment."
    },
    {
      "head": 5,
      "tail": 14,
      "type": "reports",
      "evidence": "Response was defined as a reduction of ≥50% from baseline in the QIDS-SR score at the last assessment."
    },
    {
      "head": 6,
      "tail": 27,
      "type": "reports",
      "evidence": "Intolerance was defined a priori as either leaving treatment before 4 weeks or leaving at or after 4 weeks with intolerance as the identified reason."
    },
    {
      "head": 9,
      "tail": 3,
      "type": "compares",
      "evidence": "Treatment Characteristics in Level 1, by Anxious Versus Nonanxious Depression"
    },
    {
      "head": 3,
      "tail": 21,
      "type": "has_dosage",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Maximum citalopram dosage (mg/day)"
    },
    {
      "head": 3,
      "tail": 22,
      "type": "has_dosage",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Maximum citalopram dosage (mg/day)"
    },
    {
      "head": 3,
      "tail": 23,
      "type": "has_dosage",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Maximum citalopram dosage (mg/day)"
    },
    {
      "head": 3,
      "tail": 24,
      "type": "has_dosage",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Maximum citalopram dosage (mg/day)"
    },
    {
      "head": 3,
      "tail": 25,
      "type": "has_dosage",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Maximum citalopram dosage (mg/day)"
    },
    {
      "head": 3,
      "tail": 26,
      "type": "has_dosage",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Time in treatment (weeks)"
    },
    {
      "head": 3,
      "tail": 27,
      "type": "has_dosage",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Time in treatment (weeks)"
    },
    {
      "head": 3,
      "tail": 28,
      "type": "has_dosage",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Time in treatment (weeks)"
    },
    {
      "head": 3,
      "tail": 29,
      "type": "has_dosage",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Time in treatment (weeks)"
    },
    {
      "head": 4,
      "tail": 15,
      "type": "reports",
      "evidence": "The alpha level in analyses was set at 0.05 (two-sided)."
    },
    {
      "head": 9,
      "tail": 16,
      "type": "reports",
      "evidence": "Of the 4,041 eligible participants, 2,876 constituted the evaluable sample—those who had a HAM-D score ≥14 (as assessed by research outcome assessors) and who returned for at least one postbaseline visit in Level 1 of STAR*D (see supplementary Table 1 in the data supplement that accompanies the online version of this article)."
    },
    {
      "head": 9,
      "tail": 17,
      "type": "reports",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Maximum citalopram dosage (mg/day)"
    },
    {
      "head": 9,
      "tail": 18,
      "type": "reports",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Maximum citalopram dosage (mg/day)"
    },
    {
      "head": 9,
      "tail": 20,
      "type": "reports",
      "evidence": "Of the 4,041 eligible participants, 2,876 constituted the evaluable sample—those who had a HAM-D score ≥14 (as assessed by research outcome assessors) and who returned for at least one postbaseline visit in Level 1 of STAR*D (see supplementary Table 1 in the data supplement that accompanies the online version of this article)."
    },
    {
      "head": 3,
      "tail": 30,
      "type": "reports",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Maximum citalopram dosage (mg/day)"
    },
    {
      "head": 3,
      "tail": 31,
      "type": "reports",
      "evidence": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression Dose and Treatment Anxious Depression Total (N=2,876) p No (N=1,346) Yes (N=1,530) N % N % N % Citalopram dosage at study exit (mg/day)"
    },
    {
      "head": 7,
      "tail": 120,
      "type": "affects",
      "evidence": "Patients with anxious depression made fewer visits and spent less time in treatment than those without anxious depression (Table 1)."
    },
    {
      "head": 8,
      "tail": 123,
      "type": "affects",
      "evidence": "Patients with anxious depression made fewer visits and spent less time in treatment than those without anxious depression (Table 1)."
    },
    {
      "head": 1,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "Remission rates were significantly lower in patients with anxious depression, according to both the HAM-D criterion (22.2% versus 33.4%) and the QIDS-SR criterion (27.5% versus 38.9%)."
    },
    {
      "head": 1,
      "tail": 5,
      "type": "has_outcome",
      "evidence": "Response rates were also significantly lower for patients with anxious depression (41.7% versus 52.8%)."
    },
    {
      "head": 1,
      "tail": 6,
      "type": "has_outcome",
      "evidence": "the anxious depression group had greater a frequency, intensity, and burden of side ef- fects than the nonanxious depression group, as well as more serious adverse events"
    },
    {
      "head": 7,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "Remission rates were significantly lower in patients with anxious depression"
    },
    {
      "head": 7,
      "tail": 5,
      "type": "has_outcome",
      "evidence": "Response rates were also significantly lower for patients with anxious de- pression"
    },
    {
      "head": 7,
      "tail": 6,
      "type": "has_outcome",
      "evidence": "the anxious depression group had greater a frequency, intensity, and burden of side ef- fects than the nonanxious depression group"
    },
    {
      "head": 4,
      "tail": 10,
      "type": "measured_by",
      "evidence": "Remission (score ≤7 on 17-item HAM-D)"
    },
    {
      "head": 4,
      "tail": 11,
      "type": "measured_by",
      "evidence": "Remission (score ≤5 on QIDS-SR)"
    },
    {
      "head": 5,
      "tail": 11,
      "type": "measured_by",
      "evidence": "Response (≥50% reduction from baseline on QIDS-SR)"
    },
    {
      "head": 9,
      "tail": 1,
      "type": "affects",
      "evidence": "Outcomes in Level 1, by Anxious Versus Nonanxious Depression"
    },
    {
      "head": 9,
      "tail": 4,
      "type": "reports",
      "evidence": "TABLE 2. Remission and Response in Patients in Level 1 of STAR*D, by Presence of Anxious Depression"
    },
    {
      "head": 9,
      "tail": 5,
      "type": "reports",
      "evidence": "TABLE 2. Remission and Response in Patients in Level 1 of STAR*D, by Presence of Anxious Depression"
    },
    {
      "head": 4,
      "tail": 12,
      "type": "reports",
      "evidence": "22.2% versus 33.4%"
    },
    {
      "head": 4,
      "tail": 13,
      "type": "reports",
      "evidence": "22.2% versus 33.4%"
    },
    {
      "head": 4,
      "tail": 14,
      "type": "reports",
      "evidence": "27.5% versus 38.9%"
    },
    {
      "head": 4,
      "tail": 15,
      "type": "reports",
      "evidence": "27.5% versus 38.9%"
    },
    {
      "head": 5,
      "tail": 16,
      "type": "reports",
      "evidence": "41.7% versus 52.8%"
    },
    {
      "head": 5,
      "tail": 17,
      "type": "reports",
      "evidence": "41.7% versus 52.8%"
    },
    {
      "head": 4,
      "tail": 21,
      "type": "reports",
      "evidence": "p <0.0001"
    },
    {
      "head": 4,
      "tail": 22,
      "type": "reports",
      "evidence": "Adjusted p 0.0010a"
    },
    {
      "head": 4,
      "tail": 35,
      "type": "reports",
      "evidence": "p <0.0001 0.0018b"
    },
    {
      "head": 3,
      "tail": 2,
      "type": "treats",
      "evidence": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram"
    },
    {
      "head": 87,
      "tail": 2,
      "type": "treats",
      "evidence": "sustained-release bupropion"
    },
    {
      "head": 88,
      "tail": 2,
      "type": "treats",
      "evidence": "sertraline"
    },
    {
      "head": 89,
      "tail": 2,
      "type": "treats",
      "evidence": "extended-re- lease venlafaxine"
    },
    {
      "head": 3,
      "tail": 92,
      "type": "has_dosage",
      "evidence": "at a maximal daily dose of 400 mg"
    },
    {
      "head": 88,
      "tail": 93,
      "type": "has_dosage",
      "evidence": "at a maximal daily dose of 200 mg"
    },
    {
      "head": 89,
      "tail": 94,
      "type": "has_dosage",
      "evidence": "at a maximal daily dose of 375 mg"
    },
    {
      "head": 87,
      "tail": 95,
      "type": "has_dosage",
      "evidence": "at a dose of up to 400 mg per day"
    },
    {
      "head": 90,
      "tail": 96,
      "type": "has_dosage",
      "evidence": "at a dose of up to 60 mg per day"
    },
    {
      "head": 9,
      "tail": 3,
      "type": "compares",
      "evidence": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram (in the case of the switch option only) were randomly assigned either to switch (overall N=727) to sustained-release bupropion (at a maximal daily dose of 400 mg; N=239), sertraline (at a maximal daily dose of 200 mg; N=238), or extended-re- lease venlafaxine (at a maximal daily dose of 375 mg; N= 250) or to continue taking citalopram and receive aug- mentation (overall N=565) with sustained-release bupro- pion (at a dose of up to 400 mg per day; N=279) or bus- pirone (at a dose of up to 60 mg per day; N=286)."
    },
    {
      "head": 5,
      "tail": 2,
      "type": "treats",
      "evidence": "Our results are consistent with the view that anxious de- pression is associated with specific treatment responsivity, in that patients with this subtype were less likely to achieve remission than those with nonanxious depression after antidepressant treatment, in both Levels 1 and 2 of STAR*D, regardless of treatment assignment in Level 2."
    },
    {
      "head": 1,
      "tail": 15,
      "type": "has_outcome",
      "evidence": "Our results are consistent with the view that anxious de- pression is associated with specific treatment responsivity, in that patients with this subtype were less likely to achieve remission than those with nonanxious depression after antidepressant treatment, in both Levels 1 and 2 of STAR*D, regardless of treatment assignment in Level 2."
    },
    {
      "head": 3,
      "tail": 15,
      "type": "has_outcome",
      "evidence": "Our results are consistent with the view that anxious de- pression is associated with specific treatment responsivity, in that patients with this subtype were less likely to achieve remission than those with nonanxious depression after antidepressant treatment, in both Levels 1 and 2 of STAR*D, regardless of treatment assignment in Level 2."
    },
    {
      "head": 1,
      "tail": 17,
      "type": "has_outcome",
      "evidence": "Our results are consistent with the view that anxious de- pression is associated with specific treatment responsivity, in that patients with this subtype were less likely to achieve remission than those with nonanxious depression after antidepressant treatment, in both Levels 1 and 2 of STAR*D, regardless of treatment assignment in Level 2."
    },
    {
      "head": 13,
      "tail": 15,
      "type": "has_outcome",
      "evidence": "Our results are consistent with the view that anxious de- pression is associated with specific treatment responsivity, in that patients with this subtype were less likely to achieve remission than those with nonanxious depression after antidepressant treatment, in both Levels 1 and 2 of STAR*D, regardless of treatment assignment in Level 2."
    },
    {
      "head": 21,
      "tail": 19,
      "type": "has_outcome",
      "evidence": "Also, since only outpa- tients with major depression were enrolled in the study, the clinical correlates and symptom patterns we found to be as- sociated with anxious depression may be different in inpa- tients treated for depression."
    },
    {
      "head": 1,
      "tail": 19,
      "type": "has_outcome",
      "evidence": "Also, since only outpa- tients with major depression were enrolled in the study, the clinical correlates and symptom patterns we found to be as- sociated with anxious depression may be different in inpa- tients treated for depression."
    },
    {
      "head": 1,
      "tail": 20,
      "type": "has_outcome",
      "evidence": "Similarly, it is possible that the greater side effect burden in the group with high levels of anxiety could be explained by the greater number of general medical conditions in this group."
    },
    {
      "head": 26,
      "tail": 5,
      "type": "compares",
      "evidence": "Our results are consistent with the view that anxious de- pression is associated with specific treatment responsivity, in that patients with this subtype were less likely to achieve remission than those with nonanxious depression after antidepressant treatment, in both Levels 1 and 2 of STAR*D, regardless of treatment assignment in Level 2."
    },
    {
      "head": 26,
      "tail": 1,
      "type": "compares",
      "evidence": "Our results are consistent with the view that anxious de- pression is associated with specific treatment responsivity, in that patients with this subtype were less likely to achieve remission than those with nonanxious depression after antidepressant treatment, in both Levels 1 and 2 of STAR*D, regardless of treatment assignment in Level 2."
    },
    {
      "head": 26,
      "tail": 3,
      "type": "compares",
      "evidence": "Our results are consistent with the view that anxious de- pression is associated with specific treatment responsivity, in that patients with this subtype were less likely to achieve remission than those with nonanxious depression after antidepressant treatment, in both Levels 1 and 2 of STAR*D, regardless of treatment assignment in Level 2."
    },
    {
      "head": 15,
      "tail": 31,
      "type": "measured_by",
      "evidence": "Our definition of anxious depression was based on the severity of anxiety symptoms as measured by the HAM- D anxiety/somatization factor."
    },
    {
      "head": 15,
      "tail": 33,
      "type": "reports",
      "evidence": "FIGURE 3. Time to Remission in 2,876 Patients in Level 1 of STAR*D, by Anxious Versus Nonanxious Depressiona a Log-rank statistic=41.7, p<0.0001."
    },
    {
      "head": 15,
      "tail": 34,
      "type": "reports",
      "evidence": "FIGURE 4. Time to Response in 2,876 Patients in Level 1 of STAR*D, by Anxious Versus Nonanxious Depressiona a Log-rank statistic=22.7, p<0.0001."
    },
    {
      "head": 6,
      "tail": 16,
      "type": "has_outcome",
      "evidence": "Our results are consistent with the view that anxious de- pression is associated with specific treatment responsivity, in that patients with this subtype were less likely to achieve remission than those with nonanxious depression after antidepressant treatment, in both Levels 1 and 2 of STAR*D, regardless of treatment assignment in Level 2."
    },
    {
      "head": 14,
      "tail": 16,
      "type": "has_outcome",
      "evidence": "On the other hand, the association between anxious depression and poorer treatment outcome with antidepressant monotherapy in Level 1 of STAR*D held true regardless of how we defined anxious depression."
    },
    {
      "head": 14,
      "tail": 19,
      "type": "has_outcome",
      "evidence": "On the other hand, the association between anxious depression and poorer treatment outcome with antidepressant monotherapy in Level 1 of STAR*D held true regardless of how we defined anxious depression."
    },
    {
      "head": 1,
      "tail": 19,
      "type": "has_outcome",
      "evidence": "On the other hand, the association between anxious depression and poorer treatment outcome with antidepressant monotherapy in Level 1 of STAR*D held true regardless of how we defined anxious depression."
    },
    {
      "head": 8,
      "tail": 35,
      "type": "reports",
      "evidence": "TABLE 5. Remission Rates in Level 2 of STAR*D in Patients With Anxious and Nonanxious Depression, by Treatment Option Level 2 Treatment Option Nonanxious Depression Anxious Depression Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Switch (N=727) Bupropion (sustained release) (N=239) 33.9 36.4 10.2 12.5"
    },
    {
      "head": 8,
      "tail": 36,
      "type": "reports",
      "evidence": "TABLE 5. Remission Rates in Level 2 of STAR*D in Patients With Anxious and Nonanxious Depression, by Treatment Option Level 2 Treatment Option Nonanxious Depression Anxious Depression Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Switch (N=727) Bupropion (sustained release) (N=239) 33.9 36.4 10.2 12.5"
    },
    {
      "head": 8,
      "tail": 45,
      "type": "reports",
      "evidence": "TABLE 5. Remission Rates in Level 2 of STAR*D in Patients With Anxious and Nonanxious Depression, by Treatment Option Level 2 Treatment Option Nonanxious Depression Anxious Depression Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Switch (N=727) Bupropion (sustained release) (N=239) 33.9 36.4 10.2 12.5"
    },
    {
      "head": 8,
      "tail": 46,
      "type": "reports",
      "evidence": "TABLE 5. Remission Rates in Level 2 of STAR*D in Patients With Anxious and Nonanxious Depression, by Treatment Option Level 2 Treatment Option Nonanxious Depression Anxious Depression Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Switch (N=727) Bupropion (sustained release) (N=239) 33.9 36.4 10.2 12.5"
    },
    {
      "head": 9,
      "tail": 37,
      "type": "reports",
      "evidence": "TABLE 5. Remission Rates in Level 2 of STAR*D in Patients With Anxious and Nonanxious Depression, by Treatment Option Level 2 Treatment Option Nonanxious Depression Anxious Depression Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Switch (N=727) Bupropion (sustained release) (N=239) 33.9 36.4 10.2 12.5 Sertraline (N=238) 28.5 35.7 8.3 19.6"
    },
    {
      "head": 9,
      "tail": 38,
      "type": "reports",
      "evidence": "TABLE 5. Remission Rates in Level 2 of STAR*D in Patients With Anxious and Nonanxious Depression, by Treatment Option Level 2 Treatment Option Nonanxious Depression Anxious Depression Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Switch (N=727) Bupropion (sustained release) (N=239) 33.9 36.4 10.2 12.5 Sertraline (N=238) 28.5 35.7 8.3 19.6"
    },
    {
      "head": 9,
      "tail": 47,
      "type": "reports",
      "evidence": "TABLE 5. Remission Rates in Level 2 of STAR*D in Patients With Anxious and Nonanxious Depression, by Treatment Option Level 2 Treatment Option Nonanxious Depression Anxious Depression Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Switch (N=727) Bupropion (sustained release) (N=239) 33.9 36.4 10.2 12.5 Sertraline (N=238) 28.5 35.7 8.3 19.6"
    },
    {
      "head": 9,
      "tail": 48,
      "type": "reports",
      "evidence": "TABLE 5. Remission Rates in Level 2 of STAR*D in Patients With Anxious and Nonanxious Depression, by Treatment Option Level 2 Treatment Option Nonanxious Depression Anxious Depression Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Remission, by HAM-D criteriona (%) Remission, by QIDS- SR criterionb (%) Switch (N=727) Bupropion (sustained release) (N=239) 33.9 36.4 10.2 12.5 Sertraline (N=238) 28.5 35.7 8.3 19.6"
    },
    {
      "head": 3,
      "tail": 1,
      "type": "treats",
      "evidence": "Ms. D was started on a course of antidepressant therapy with citalopram."
    },
    {
      "head": 3,
      "tail": 5,
      "type": "has_outcome",
      "evidence": "Within a few days of starting the medication, she called us expressing her concerns about the side effects that she was experiencing"
    },
    {
      "head": 3,
      "tail": 6,
      "type": "has_outcome",
      "evidence": "in particular, she was worried about the worsening of her insomnia and her nervousness."
    },
    {
      "head": 3,
      "tail": 7,
      "type": "has_outcome",
      "evidence": "in particular, she was worried about the worsening of her insomnia and her nervousness."
    },
    {
      "head": 3,
      "tail": 8,
      "type": "has_outcome",
      "evidence": "She also reported a number of physical symptoms, including dryness of mouth and constipation."
    },
    {
      "head": 3,
      "tail": 9,
      "type": "has_outcome",
      "evidence": "She also reported a number of physical symptoms, including dryness of mouth and constipation."
    },
    {
      "head": 3,
      "tail": 10,
      "type": "has_outcome",
      "evidence": "She also reported a number of physical symptoms, including dryness of mouth and constipation."
    },
    {
      "head": 13,
      "tail": 11,
      "type": "treats",
      "evidence": "a benzodiazepine was prescribed, which brought about a signiﬁcant improvement in her insomnia and agitation."
    },
    {
      "head": 13,
      "tail": 6,
      "type": "has_outcome",
      "evidence": "a benzodiazepine was prescribed, which brought about a signiﬁcant improvement in her insomnia and agitation."
    },
    {
      "head": 13,
      "tail": 12,
      "type": "has_outcome",
      "evidence": "a benzodiazepine was prescribed, which brought about a signiﬁcant improvement in her insomnia and agitation."
    },
    {
      "head": 3,
      "tail": 14,
      "type": "has_outcome",
      "evidence": "After 6 weeks of combined treatment with citalopram and a benzodiazepine, Ms. D reported a signiﬁcant improvement in all her symptoms, and remission was achieved at the end of the 10th week of treatment."
    },
    {
      "head": 15,
      "tail": 1,
      "type": "has_outcome",
      "evidence": "Ms. D, a 45-year-old married woman, presented to our clinic with the following chief complaint: “I am very nervous, stressed out, and I cry a lot.” She also reported poor sleep, frequent awakenings, diminished appetite, excessive worrying, headaches and muscle aches, feelings of worthlessness and pessimism, inability to enjoy things, psychomotor agitation, and restlessness. She endorsed some feelings of hopelessness but denied having thoughts of death or suicide. Ms. D had a history of generalized anxiety since childhood, but this was appar- ently her ﬁrst episode of major depression."
    },
    {
      "head": 15,
      "tail": 2,
      "type": "has_outcome",
      "evidence": "Ms. D had a history of generalized anxiety since childhood, but this was appar- ently her ﬁrst episode of major depression."
    },
    {
      "head": 16,
      "tail": 17,
      "type": "compares",
      "evidence": "Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D."
    },
    {
      "head": 3,
      "tail": 18,
      "type": "reports",
      "evidence": "After 6 weeks of combined treatment with citalopram and a benzodiazepine, Ms. D reported a signiﬁcant improvement in all her symptoms, and remission was achieved at the end of the 10th week of treatment."
    },
    {
      "head": 14,
      "tail": 19,
      "type": "reports",
      "evidence": "After 6 weeks of combined treatment with citalopram and a benzodiazepine, Ms. D reported a signiﬁcant improvement in all her symptoms, and remission was achieved at the end of the 10th week of treatment."
    },
    {
      "head": 3,
      "tail": 20,
      "type": "reports",
      "evidence": "She and her physician agreed that she would maintain the treatment combination for at least 6 months."
    },
    {
      "head": 1,
      "tail": 2,
      "type": "affects",
      "evidence": "What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder"
    },
    {
      "head": 8,
      "tail": 6,
      "type": "treats",
      "evidence": "Anxious depression in elderly patients: response to antidepressant treatment"
    },
    {
      "head": 10,
      "tail": 12,
      "type": "treats",
      "evidence": "Achieving remission with venlafaxine and fluoxetine in major depression"
    },
    {
      "head": 11,
      "tail": 12,
      "type": "treats",
      "evidence": "Achieving remission with venlafaxine and fluoxetine in major depression"
    },
    {
      "head": 10,
      "tail": 9,
      "type": "has_outcome",
      "evidence": "Achieving remission with venlafaxine and fluoxetine in major depression"
    },
    {
      "head": 11,
      "tail": 9,
      "type": "has_outcome",
      "evidence": "Achieving remission with venlafaxine and fluoxetine in major depression"
    },
    {
      "head": 12,
      "tail": 13,
      "type": "has_outcome",
      "evidence": "Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms"
    },
    {
      "head": 14,
      "tail": 16,
      "type": "treats",
      "evidence": "Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression"
    },
    {
      "head": 15,
      "tail": 16,
      "type": "treats",
      "evidence": "Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression"
    },
    {
      "head": 17,
      "tail": 16,
      "type": "affects",
      "evidence": "Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression"
    },
    {
      "head": 20,
      "tail": 19,
      "type": "has_outcome",
      "evidence": "Psychosocial and clinical predictors of unipolar depression outcome in older adults"
    },
    {
      "head": 21,
      "tail": 14,
      "type": "compares",
      "evidence": "Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study"
    },
    {
      "head": 21,
      "tail": 15,
      "type": "compares",
      "evidence": "Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study"
    },
    {
      "head": 22,
      "tail": 25,
      "type": "treats",
      "evidence": "Fluoxetine versus sertraline and paroxetine in major depression"
    },
    {
      "head": 23,
      "tail": 25,
      "type": "treats",
      "evidence": "Fluoxetine versus sertraline and paroxetine in major depression"
    },
    {
      "head": 24,
      "tail": 25,
      "type": "treats",
      "evidence": "Fluoxetine versus sertraline and paroxetine in major depression"
    },
    {
      "head": 22,
      "tail": 26,
      "type": "has_outcome",
      "evidence": "Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression"
    },
    {
      "head": 22,
      "tail": 27,
      "type": "has_outcome",
      "evidence": "Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression"
    },
    {
      "head": 23,
      "tail": 26,
      "type": "has_outcome",
      "evidence": "Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression"
    },
    {
      "head": 23,
      "tail": 27,
      "type": "has_outcome",
      "evidence": "Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression"
    },
    {
      "head": 24,
      "tail": 26,
      "type": "has_outcome",
      "evidence": "Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression"
    },
    {
      "head": 24,
      "tail": 27,
      "type": "has_outcome",
      "evidence": "Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression"
    },
    {
      "head": 29,
      "tail": 30,
      "type": "affects",
      "evidence": "Clinical and demographic features of atypical depression in outpatients with major depressive disorder"
    },
    {
      "head": 29,
      "tail": 31,
      "type": "affects",
      "evidence": "Clinical and demographic features of atypical depression in outpatients with major depressive disorder"
    },
    {
      "head": 32,
      "tail": 33,
      "type": "treats",
      "evidence": "Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D"
    },
    {
      "head": 1,
      "tail": 2,
      "type": "has_outcome",
      "evidence": "for the STAR*D Investigators: Self-rated global mea- sure of the frequency, intensity, and burden of side effects."
    },
    {
      "head": 8,
      "tail": 3,
      "type": "treats",
      "evidence": "Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depres- sion."
    },
    {
      "head": 5,
      "tail": 3,
      "type": "treats",
      "evidence": "Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depres- sion."
    },
    {
      "head": 6,
      "tail": 3,
      "type": "treats",
      "evidence": "Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depres- sion."
    },
    {
      "head": 7,
      "tail": 3,
      "type": "treats",
      "evidence": "Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depres- sion."
    },
    {
      "head": 8,
      "tail": 10,
      "type": "has_outcome",
      "evidence": "Medication augmentation after the failure of SSRIs for depression."
    },
    {
      "head": 9,
      "tail": 10,
      "type": "has_outcome",
      "evidence": "Medication augmentation after the failure of SSRIs for depression."
    },
    {
      "head": 1,
      "tail": 5,
      "type": "compares",
      "evidence": "Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depres- sion."
    },
    {
      "head": 1,
      "tail": 6,
      "type": "compares",
      "evidence": "Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depres- sion."
    },
    {
      "head": 1,
      "tail": 7,
      "type": "compares",
      "evidence": "Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depres- sion."
    }
  ],
  "raw_responses": [
    "{\n  \"entities\": [\n    {\n      \"id\": 1,\n      \"text\": \"anxious depression\",\n      \"type\": \"medical_condition\"\n    },\n    {\n      \"id\": 2,\n      \"text\": \"major depression\",\n      \"type\": \"medical_condition\"\n    },\n    {\n      \"id\": 3,\n      \"text\": \"citalopram\",\n      \"type\": \"medication\"\n    },\n    {\n      \"id\": 4,\n      \"text\": \"switching\",\n      \"type\": \"treatment_type\"\n    },\n    {\n      \"id\": 5,\n      \"text\": \"augmentation\",\n      \"type\": \"treatment_type\"\n    },\n    {\n      \"id\": 6,\n      \"text\": \"remission\",\n      \"type\": \"outcome\"\n    },\n    {\n      \"id\": 7,\n      \"text\": \"respond\",\n      \"type\": \"outcome\"\n    },\n    {\n      \"id\": 8,\n      \"text\": \"poorer treatment outcomes\",\n      \"type\": \"outcome\"\n    },\n    {\n      \"id\": 9,\n      \"text\": \"side effects\",\n      \"type\": \"outcome\"\n    },\n    {\n      \"id\": 10,\n      \"text\": \"dropout\",\n      \"type\": \"outcome\"\n    },\n    {\n      \"id\": 11,\n      \"text\": \"patients with anxious depression\",\n      \"type\": \"patient_group\"\n    },\n    {\n      \"id\": 12,\n      \"text\": \"patients with nonanxious depression\",\n      \"type\": \"patient_group\"\n    },\n    {\n      \"id\": 13,\n      \"text\": \"STAR*D\",\n      \"type\": \"study\"\n    },\n    {\n      \"id\": 14,\n      \"text\": \"HAM-D\",\n      \"type\": \"measure\"\n    },\n    {\n      \"id\": 15,\n      \"text\": \"QIDS-SR\",\n      \"type\": \"measure\"\n    },\n    {\n      \"id\": 16,\n      \"text\": \"0.014 to 0.020\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 17,\n      \"text\": \"≥7\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 18,\n      \"text\": \"N=2,876\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 19,\n      \"text\": \"N=1,346\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 20,\n      \"text\": \"N=1,530\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 21,\n      \"text\": \"0.0007\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 22,\n      \"text\": \"15.7\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 23,\n      \"text\": \"15.6\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 24,\n      \"text\": \"15.7\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 25,\n      \"text\": \"31.5\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 26,\n      \"text\": \"25.4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 27,\n      \"text\": \"28.2\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 28,\n      \"text\": \"31.4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 29,\n      \"text\": \"32.5\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 30,\n      \"text\": \"32.0\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 31,\n      \"text\": \"21.4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 32,\n      \"text\": \"26.5\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 33,\n      \"text\": \"24.1\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 34,\n      \"text\": \"<0.0001\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 35,\n      \"text\": \"14.7\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 36,\n      \"text\": \"16.1\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 37,\n      \"text\": \"15.5\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 38,\n      \"text\": \"32.4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 39,\n      \"text\": \"23.6\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 40,\n      \"text\": \"27.7\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 41,\n      \"text\": \"41.1\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 42,\n      \"text\": \"40.9\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 43,\n      \"text\": \"41.0\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 44,\n      \"text\": \"11.8\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 45,\n      \"text\": \"19.4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 46,\n      \"text\": \"15.8\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 47,\n      \"text\": \"<0.0001\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 48,\n      \"text\": \"20.4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 49,\n      \"text\": \"20.4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 50,\n      \"text\": \"20.4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 51,\n      \"text\": \"46.5\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 52,\n      \"text\": \"36.2\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 53,\n      \"text\": \"41.0\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 54,\n      \"text\": \"27.2\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 55,\n      \"text\": \"32.8\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 56,\n      \"text\": \"30.2\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 57,\n      \"text\": \"5.9\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 58,\n      \"text\": \"10.6\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 59,\n      \"text\": \"8.4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 60,\n      \"text\": \"2.8\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 61,\n      \"text\": \"5.1\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 62,\n      \"text\": \"4.0\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 63,\n      \"text\": \"0.0020\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 64,\n      \"text\": \"1\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 65,\n      \"text\": \"2\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 66,\n      \"text\": \"3\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 67,\n      \"text\": \"18\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 68,\n      \"text\": \"40\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 69,\n      \"text\": \"58\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 70,\n      \"text\": \"0\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 71,\n      \"text\": \"4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 72,\n      \"text\": \"4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 73,\n      \"text\": \"3\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 74,\n      \"text\": \"5\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 75,\n      \"text\": \"8\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 76,\n      \"text\": \"13\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 77,\n      \"text\": \"23\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 78,\n      \"text\": \"36\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 79,\n      \"text\": \"4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 80,\n      \"text\": \"2\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 81,\n      \"text\": \"6\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 82,\n      \"text\": \"1\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 83,\n      \"text\": \"1\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 84,\n      \"text\": \"2\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 85,\n      \"text\": \"0\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 86,\n      \"text\": \"6\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 87,\n      \"text\": \"6\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 88,\n      \"text\": \"20\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 89,\n      \"text\": \"1.5\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 90,\n      \"text\": \"37\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 91,\n      \"text\": \"2.4\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 92,\n      \"text\": \"57\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 93,\n      \"text\": \"2.0\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 94,\n      \"text\": \"0.0734\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 95,\n      \"text\": \"14.6\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 96,\n      \"text\": \"19.2\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 97,\n      \"text\": \"17.0\",\n      \"type\": \"quantitative_result\"\n    },\n    {\n      \"id\": 98,\n      \"text\": \"0.0013\",\n      \"type\": \"quantitative_result\"\n    }\n  ],\n  \"relationships\": [\n    {\n      \"head\": 3,\n      \"tail\": 2,\n      \"type\": \"treats\",\n      \"evidence\": \"Consistent with much of the literature (10–13), we found in Level 1 of STAR*D that patients with anxious depression were less likely to respond or to remit with citalopram treatment than those with nonanxious depression.\"\n    },\n    {\n      \"head\": 11,\n      \"tail\": 7,\n      \"type\": \"has_outcome\",\n      \"evidence\": \"Consistent with much of the literature (10–13), we found in Level 1 of STAR*D that patients with anxious depression were less likely to respond or to remit with citalopram treatment than those with nonanxious depression.\"\n    },\n    {\n      \"head\": 11,\n      \"tail\": 6,\n      \"type\": \"has_outcome\",\n      \"evidence\": \"Consistent with much of the literature (10–13), we found in Level 1 of STAR*D that patients with anxious depression were less likely to respond or to remit with citalopram treatment than those with nonanxious depression.\"\n    },\n    {\n      \"head\": 3,\n      \"tail\": 8,\n      \"type\": \"has_outcome\",\n      \"evidence\": \"Consistent with much of the literature (10–13), we found in Level 1 of STAR*D that patients with anxious depression were less likely to respond or to remit with citalopram treatment than those with nonanxious depression.\"\n    },\n    {\n      \"head\": 12,\n      \"tail\": 7,\n      \"type\": \"has_outcome\",\n      \"evidence\": \"Consistent with much of the literature (10–13), we found in Level 1 of STAR*D that patients with anxious depression were less likely to respond or to remit with citalopram treatment than those with nonanxious depression.\"\n    },\n    {\n      \"head\": 12,\n      \"tail\": 6,\n      \"type\": \"has_outcome\",\n      \"evidence\": \"Consistent with much of the literature (10–13), we found in Level 1 of STAR*D that patients with anxious depression were less likely to respond or to remit with citalopram treatment than those with nonanxious depression.\"\n    },\n    {\n      \"head\": 11,\n      \"tail\": 6,\n      \"type\": \"has_outcome\",\n      \"evidence\": \"In Level 2 of STAR*D, patients with anxious depression were also less likely than those with nonanxious depression to achieve remission, regardless of whether their Level 2 treatment was a switch option or an augmentation option.\"\n    },\n    {\n      \"head\": 12,\n      \"tail\": 6,\n      \"type\": \"has_outcome\",\n      \"evidence\": \"In Level 2 of STAR*D, patients with anxious depression were also less likely than those with nonanxious depression to achieve remission, regardless of whether their Level 2 treatment was a switch option or an augmentation option.\"\n    },\n    {\n      \"head\": 11,\n      \"tail\": 9,\n      \"type\": \"has_outcome\",\n      \"evidence\": \"Side effect frequency, intensity, and burden in Level 1 were greater among patients with anxious depression than among those with nonanxious depression, as were serious adverse events, including those of a psychiatric nature.\"\n    },\n    {\n      \"head\": 11,\n      \"tail\": 10,\n      \"type\": \"has_outcome\",\n      \"evidence\": \"Perhaps patients whose illness included anxious features were more sensitive to somatic changes occurring during antidepressant treatment, and they may have been more likely to drop out on encountering side effects.\"\n    },\n    {\n      \"head\": 6,\n      \"tail\": 14,\n      \"type\": \"measured_by\",\n      \"evidence\": \"Table 5 summarizes the remission rates (based on the HAM-D or the QIDS-SR criteria) by Level 2 treatment and by whether anxious depression was present at entry into Level 2.\"\n    },\n    {\n      \"head\": 6,\n      \"tail\": 15,\n      \"type\": \"measured_by\",\n      \"evidence\": \"Table 5 summarizes the remission rates (based on the HAM-D or the QIDS-SR criteria) by Level 2 treatment and by whether anxious depression was present at entry into Level 2.\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 18,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 19,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 20,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 21,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 22,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 23,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 24,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 25,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 26,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 27,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 28,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 29,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 30,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 31,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 32,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 33,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 34,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 35,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 36,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 37,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 38,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 39,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 40,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 41,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 42,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 43,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 44,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 45,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 46,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 47,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 48,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 49,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 50,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 51,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 52,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence of Anxious Depression Measure Anxious Depression Total (N=2,876) No (N=1,346) Yes (N=1,530) N % N % N % p\"\n    },\n    {\n      \"head\": 9,\n      \"tail\": 53,\n      \"type\": \"reports\",\n      \"evidence\": \"TABLE 4. Side Effects and Adverse Events in Patients in Level 1 of STAR*D, by Presence"
  ]
}